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ABSTRACT 
 
The aim of this study was to examine how inflammation and adaptation change 
expression of neurotransmitters in the enteric nervous system. 
Immunohistochemical techniques have been applied to reveal specific 
neurotransmitter and neuropeptide systems of the human and pig intestine. 
GAP-43 (growth- associated protein-43), PGP 9.5 (protein gene product 9.5), 
NSE (neuron specific enolase) and synaptophysin were evaluated as general 
neuronal markers in the human gut by using computerized morphometric 
analysis. Changes in neuropeptide-containing innervation caused by ulcerative 
colitis were examined in patient specimens. The expression of the three nitric 
oxide synthase (NOS) isoforms in ulcerative colitis colon and the expression of 
NOS-2 and NOS- 3 in pouchitis were examined. The specimens were 
harvested in operations of ulcerative colitis patients and the control specimens 
from patients operated for colon tumors. Ileum reservoir biopsies were taken 
during endoscopy. Changes in neuropeptide-containing innervation after 
massive proximal small bowel resection during adaptation were investigated 
quantitatively in the pig. 
 
GAP-43 turned out to be a universal neuronal marker in the mature human 
intestine. It reveals more numerous and thicker nerve fibers than PGP 9.5, 
synaptophysin or NSE. In contrast, NSE is a superior marker of neuronal 
somata. Ulcerative colitis colon does not significantly change the total number 
of nerve fibers in the colon. However, the density of substance P-containing 
nerve terminals specifically increases in the mucosa. NOS-1 disappears 
selectively from the nerves of muscularis mucosae of ulcerative colitis colon. 
NOS-2 level increases in the epithelium of ulcerative colitis colon in relation to 
the severity of the disease. Ulcerative colitis colon causes an increase in the 
number of vascular profiles, and a relative decrease in the level of NOS-3 in 
the lamina propria. NOS-2 is induced in pouchitis and correlates with both the 
clinical degree of pouchitis and with the severity of acute inflammation. NOS-3 
immunoreactive vascular profiles increase in pouchitis. The present series of 
studies demonstrate that substance P and NO may play substantial roles in the 
pathogenesis of ulcerative colitis and pouchitis. Massive resection induces 
significant changes in the neuropeptide-containing innervation in the intestinal 
mucosa and muscle layer. The changes are specific for VIP, galanin and 
enkephalin and are compatible with altered motor activity and mucosal function 
in the remaining intestine. 
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INTRODUCTION 
 
The gut is innervated by the enteric nervous system, which controls the 
motility, exocrine and endocrine secretion, microcirculation and is also involved 
in regulation of immune and inflammatory processes 1. 
 
The pattern of innervation can be conveniently examined in full thickness 
biopsy specimens of the intestine. Classical histological methods, such as the 
silver staining 2 can be used to reveal neurons or nerve fibers, although these 
techniques are tedious to perform, they are nonspecific and they do not allow 
immunohistochemical colocalization studies. By using immunohistochemical 
techniques we can observe specifically neurotransmitters and -peptides in 
neurons and nerve fibers 3. Examination of specific neuronal markers, antigens 
expressed exclusively by the nervous tissue, allows us to estimate changes 
involving the gut innervation as a whole. 
 
Neuron-specific enolase (NSE) and protein gene product 9.5 (PGP 9.5) are 
widely used neuronal markers in the human gut 4-6. Synaptophysin is a 
structural component of synaptic vesicles, but it has been used as a marker of 
neurons as well 7. Recently it has been shown that GAP-43 is abundantly 
expressed in the autonomic neurons and nerve fibers, as well as in the enteric 
nervous system 8; 9 of the adult rat. The specificity and sensitivity of these 
markers in the human gut is not known. In the study I we evaluate GAP-43 as a 
general neuronal marker in the mature human gut, its colocalization with 
neuropeptides, and its usefulness in computerized morphometric analysis of 
the gut innervation in comparison with two other neuronal markers, PGP 9.5 
and NSE. 
 
Nitric oxide (NO) is both a physiological messenger molecule and a cytotoxic 
agent. It has many physiological functions in the intestine. It is a 
neurotransmitter; it regulates the circulation and participates in defense 
mechanisms 10-13.NO is produced by three different isoforms of the nitric oxide 
synthase (NOS). A constitutive nitric oxide synthase is present in neurons 
(NOS-1)14; 15. The function of NO produced by NOS-1 is relaxation of the 
smooth muscle 16-18. Another constitutive NOS isoform in ubiquitously localized 
in the vascular endothelium (NOS-3) 13.  
 
Ulcerative colitis (UC) is an inflammatory, ulcerating process in the mucosa of 
colon. The precise etiology is unknown, but it is obvious that a number of 
mediators and cytokines are responsible for many of the clinical manifestations 
of UC 19. Changes in innervation have been reported in inflammatory bowel 
disease 20-24. Previous studies by our group have revealed increased number 
of substance P-immunoreactive nerve fibers in the mucosa of UC colon 25. In 
study II we examine the changes in the innervation of UC colon to find out how 
specific the increase in the density of innervation is for substance P. NOS-2 
expression is induced in inflammatory bowel diseases including UC 26. It has 
 Introduction  
10 
remained unknown whether NOS-1 or NOS-3 undergoes changes in UC. In 
study III we investigate expression of all three isoforms of NOS in UC.  
 
Abdominal colectomy with ileal pouch-anal anastomosis (IPAA) has become 
the surgical treatment of choice for most patients with UC. The most frequent 
long-term complication of IPAA performed on UC patients is inflammation of 
the ileal reservoir, termed “pouchitis”27; 28. In study IV we examine whether NO 
production is induced in pouchitis, whether it varies in different clinical forms of 
pouchitis and whether it correlates with the histopathological changes of 
pouchitis. 
 
After massive small bowel resection, the remaining intestine undergoes both 
morphological and functional changes 29-32. During this process, called 
adaptation, secretory and absorptive functions as well as motility of the 
intestine change. The study V was performed to reveal changes occurring in 
neuropeptide innervation pattern after massive small bowel resection. 
 
 
 Review of the literature 
 
 
11
 
REVIEW OF THE LITERATURE 
 
NITRIC OXIDE 
 
Synthesis and properties 
Nitric oxide (NO) is one of the smallest molecules in nature. In 1987-88 it was 
discovered that vascular endothelial cells are able to synthesize NO from L-
arginine 33; 34. Following studies revealed that NO can be synthesized by many 
mammalian cells and it modulates immune function, blood vessel dilatation, 
and neurotransmission 35. 
 
Arginine is converted to citrulline by nitric oxide synthase (NOS) in a two-step 
enzyme reaction via the formation of the intermediate Nω-hydroksy-L-arginine 
and finally release of NO. NOS enzyme exists in three isoforms encoded by 
distinct genes 35.  
 
Types 1 (nNOS) and 3 (eNOS) are constitutive and present in the neural tissue 
and in the vascular endothelium, respectively. NOS-1 and NOS-3 are regulated 
at post-translational level by calmodulin via Ca++-dependent mechanism 35. 
Type 2 NOS (iNOS) is Ca++-independent and is induced by bacterial 
endotoxins and cytokines in macrophages, endothelium, smooth muscle, liver, 
fibroblast, and neutrophils 35; 36 . Activity of NOS-1 and NOS-3 produces low 
levels of NO for a short period of time. NOS -2 when induced provides a 
continuous supply of high levels of NO. 
 
NO is uncharged and it diffuses freely across cell membranes. In biological 
systems its half-life is less than 30 s. NO is a less reactive than many free 
radicals and it cannot react with itself 37. 
 
NO mediates its effects as a physiological messenger via production of cGMP 
by activating guanylate cyclase 38. Interactions of NO with thiol groups may 
also provide a mechanism whereby NO can be transported to the target cell 37. 
Nitrosylation of thiol proteins may also be involved in remodeling of axon 
terminals 39. Under conditions of oxidative stress, e.g. when high levels of NO 
are synthesized by NOS-2 and intracellular levels of superoxides are high, the 
intracellular thiol pool is depleted. NO can react with superoxide (O2-) to 
produce peroxynitrite (ONOO-) and subsequently the hydroxyl radical, which 
are both more toxic than NO itself 37. Peroxynitrite is a highly toxic substance 
oxidizing a variety of molecules and triggering cytotoxic processes including 
lipid peroxidation and DNA damage 40. NO can inhibit enzyme activity be 
reacting with Fe-S groups or R-SH groups. Nitrosylation of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) results in irreversible ADP-ribosylation 37. 
NO can also cause deamination of DNA resulting in damage that activates 
polyADP-ribose synthetase (PARS). These interactions cause cytostasis, 
energy depletion, mutagenesis and ultimately cell death.11; 12 (Figure1). 
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NOS-2 and intestine  
NOS-2 has not been demonstrated in the normal human intestine. However 
NOS-2 expression is induced in inflammatory bowel disease 26, intestinal 
infections 45, and in celiac disease 46. 
 
NOS-3 and intestine 
NOS-3 is localized in the vascular endothelium. NO produced by NOS-3 is 
responsible for vasodilatation through relaxation of the vascular smooth 
muscle, and it contributes to regulation of blood fluidity and prevention of 
platelet aggregation 13. Experimental evidence suggests that NOS-3 activity is 
regulated by bloodborn agonists activating endothelial receptors, shear stress 
or low oxygen tension 47; 48. 
 
 
ENTERIC NERVOUS SYSTEM 
 
The enteric nervous system (ENS) represents one of the three divisions of the 
autonomic nervous system. The ENS is composed of several nerve plexuses in 
the different wall layers of the gut and of their interconnections 49. 
 
The enteric nervous system is primarily derived from cells of the vagal segment 
of the neural crest that migrate to the cranial portion of the gut and 
subsequently move caudally to populate the gastrointestinal tract. The ganglia 
of the hindgut receive an additional contribution from the sacral segment of 
neural crest 50. 
 
Meissner (1857) and Auerbach (1864) first described the rich neuronal network 
composed of ganglia and nerve bundles forming the submucous and the 
myenteric plexuses in the gut wall. Bayliss and Starling (1899) provided further 
evidence for this network, which is not only the target of various "extrinsic" 
pathways, projecting via the sympathetic and parasympathetic divisions of the 
autonomic nervous system, but also contains an exceedingly high number of 
intramural neurons 51. It is this "intrinsic" nerve network, running uninterruptedly 
from the oral cavity to the anal canal, which Langley (1921) called "the enteric 
nervous system". 
 
The majority of nerve cell bodies of the ENS are confined to the ganglia of 
submucous (Meissner) and myenteric (Auerbach) plexuses and constitute the 
intrinsic component of the enteric nervous system. The myenteric plexus is 
located between the two muscle layers, the inner circular and the outer 
longitudinal one. The submucous plexus is located between the muscularis 
mucosae and the circular muscle layer. A sparse subserous plexus is found in 
the mesentery and on the outside of the muscle layer. Mucosal plexus is 
comprised of nerve fibers in lamina propria 52.  
 
The neurons that make up the enteric nervous system can be classified as 
intrinsic afferent neurons (sensory), interneurons, and motor neurons. The 
intrinsic afferent neurons form the sensory limb of all intrinsic motor and 
  Review of the literature  
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secretomotor reflex pathways and they are located in both the myenteric and 
submucous plexuses. Interneurons connect the intrinsic afferent neurons with 
the motor or secretomotor neurons. Interneurons involved in motor reflexes are 
directed orally or anally, and called ascending or descending, respectively. The 
motor neurons are either excitatory or inhibitory. The excitatory motor neurons 
project locally or orally to the circular muscle layer, and their neurotransmitters 
are acetylcholine and substance P. The inhibitory motor neurons in the circular 
muscle layer project anally and contain vasoactive intestinal polypeptide (VIP) 
and nitric oxide (NO) 49; 53; 54. 
 
In addition to entirely intrinsic neurons, the gastrointestinal wall contains 
extrinsic nerve fibers, which can be divided in motor (efferent) and sensory 
(afferent) pathways of the parasympathetic and sympathetic divisions. The 
parasympathetic motor pathways consist of branches of the vagus nerve that 
control the motor and secretomotor functions of the upper gastrointestinal tract 
and of the sacral parasympathetic nerves that regulate the functions of the 
distal colon and rectum. The parasympathetic efferent neurons are all 
cholinergic and have an excitatory effect on the myenteric neurons. The 
sympathetic efferent fibers entering the gut are postganglionic fibers with cell 
bodies in the prevertebral ganglia. They are noradrenergic and they innervate 
secretomotor neurons, presynaptic cholinergic nerve endings, submucosal 
blood vessels and gastrointestinal sphincters. Primary afferent neurons are 
sensory neurons that carry information from the gut to the central nervous 
system. Their fibers are located in the vagal and splanchnic nerves. The 
primary vagal afferent nerve endings in the muscle layer are sensitive to 
mechanical distension of the gut, while those in the mucosa are sensitive to 
luminal concentration of glucose, amino acids, or long-chain fatty acids, some 
reacting to a wide variety of chemical and mechanical stimuli. The cell bodies 
of the vagal primary afferent neurons are located in the nodose ganglia. 
Splanchnic primary afferent neurons have their cell bodies in the dorsal root 
ganglia. They are nociceptors and are involved in sensing pain in the 
gastrointestinal tract. They respond to high-intensity mechanical or chemical 
stimuli that damage or threaten the tissue 53-55. These neurons contain 
substance P and also CGRP 56. Substance P and CGRP may be important in 
the activation of nociceptive afferent neurons in conditions such as noncardiac 
chest pain, colon irritabile syndrome, intestinal ischemia, and inflammatory 
bowel disease 54. Splanchnic primary afferent neurons can also act directly on 
the nearby effector systems. They have long, bifurcated processes that allow 
them to induce the axon reflex. In this reflex the activation of one limb of the 
bifurcated axon causes excitation to spread to the collateral limb, which then 
releases neurotransmitters such as substance P to produce effects on the 
nearby cells 57. The axon reflex is important in mucosal vasodilatation, 
duodenal secretion, and mast-cell degranulation 54; 58-60. 
 
This intrinsic nervous network is capable of selecting and initiating highly 
coordinated functional responses, while the connections and projections 
from/to the other parts of the nervous system have a modulatory role 61. Most 
diverse digestive functions are regulated by the enteric nervous system, 
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including, motility, many secretory and absorptive processes, mesenteric 62 as 
well as local vasomotor responses 63 and mucosal defense 61. 
 
Changes in the density of innervation are caused by various pathological 
processes, such as ulcerative colitis 25, irradiation 64,Chagas´s disease 65, 
achalasia 66; 67, Hirschsprung´s disease 68, or intestinal neuronal dysplasia 69. 
 
Neurotransmitters 
More than 20 putative neurotransmitters have been found in the intestine either 
by immunohistochemistry, radioimmunoassay or bioassay (Table 1) 49. The 
evidence that peptides are located in intestinal neurons and nerves relies on 
immunohistochemical studies 70. Most intestinal neurons contain several 
neurotransmitters, and distinctive patterns of transmitter colocalization have 
been observed 71-73. Neurotransmitter functions have been defined only for 
acetylcholine, substance P, vasoactive intestinal polypeptide, and nitric oxide 
54
. A wide variety of neurons that have different functions may use the same 
neurotransmitter 73.  
 
Substance P 
Substance P was the first of the gut neuropeptides. In 1931 von Euler and 
Gaddum reported that extracts of horse intestine contained material that 
stimulated atropine-resistant contractions of rabbit ileum 74. 1970 substance P 
was isolated from hypothalamic tissue and chemically characterized as an 
undecapeptide, and was shown to have potent vasodilator properties 75. 
Substance P occurs widely in the brain and spinal cord as well as in the gut 70. 
Substance P belongs to the tackykinins, which are a family of small biologically 
active peptides whose principal mammalian members are substance P, 
neurokinin A (NKA) and neurokinin B (NKB). Substance P and NKA are in 
abundance in the digestive system. These peptides are derived from precursor 
proteins, the preprotachykinins, which are coded by two different genes. 
Tachykinins act through specific tachykinin receptors 76. 
 
Substance P is expressed in both the intrinsic and the extrinsic neurons 71; 72; 
76
. The latter are mainly located in the dorsal root ganglia 77. The intrinsic 
afferent nerves located in the submucous plexus contain, in addition to 
substance P, also acetylcholine or dynorphin. The intrinsic afferent nerves 
located in the myenteric plexus contain substance P and calbindin. Stimulation 
of these neurons releases substance P in the enteric ganglia, which activates 
secretomotor pathways, but also within the mucosa to directly influence 
epithelial function 56. The intrinsic nerves may be responsible for triggering 
enteric reflexes to luminal stimuli 70. The primary afferent nerve fibers contain 
substance P and CGRP (calcitonin-gene-related peptide 78. There is relatively 
little change in substance P concentrations in the gut in capsaicin-pretreated 
animals (capsaicin depletes substance P storage granules in extrinsic sensory 
nerve terminals of the gut). This indicates that the major pool is intrinsic 
neurons (figure 2) 56. Excitatory motor neurons contain both substance P and 
acetylcholine. Substance P may act both on the enteric neurons and on the 

 Review of the literature 
 
 
17
The neurons responsible for the descending inhibition of peristalsis in the 
circular muscle layer contain VIP and NO 70; 85. 
Galanin  
Galanin is present in secretomotor neurons and descending interneurons as 
well as in some inhibitory motor neurons of the human intestine86. 
 
Enkephalin 
Enkephalin and related opioid peptides are present in interneurons and motor 
neurons. In most regions these substances probably provide feedback 
inhibition of transmitter release and inhibit intestinal motility. Opiates have 
potent antisecretory effects in small intestine, which is thought to be the 
mechanism of the antidiarrheal actions of these compounds 86. 
 
Somatostatin  
No clearly defined role has been described for somatostatin in spite of its 
widespread distribution in the enteric neurons 86. 
 
Calcitonin gene-related peptide  
CGRP is present in some secretomotor neurons and in some interneurons. It is 
also colocalized with substance P in the extrinsic sensory neurons 70. 
 
Acetylcholine 
Acetylcholine is the most abundant transmitter substance in the gut. It is the 
primary excitatory transmitter of the muscle, intestinal epithelium, some gut 
endocrine cells and it also acts at neuroneuronal synapses 86. 
 
Noradrenaline 
Noradrenaline is located in the postganglionic sympathetic terminals and it 
inhibits motility in non-sphincter regions, contracts the smooth muscle of the 
sphincters, inhibits secretomotor reflexes and is also vasoconstrictor 86. 
 
NO 
Nitric oxide is a co-transmitter in enteric inhibitory neurons 15-17; 43; 85. It is also a 
possible transmitter at neuroneuronal synapses. It colocalized with VIP 44.  
 
Additionally, other mediators, such as ATP, CCK, angiotensin, dynorphin, 
GABA, GRP, 5-HT, neuromedin U, and NPY have been described in the 
gastrointestinal tract 70; 86. 
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Table 1. Putative neurotransmitters in the mammalian enteric nervous  
 
Acetylcholine 
 
The most common transmitter in the gut. Present in motor, 
secretomotor and interneurons Primary excitatory transmitter 
to the muscle, to the epithelium, to some gut endocrine cells, 
and at neuroneuronal synapses.  
AMINES  
Noradrenaline Noradrenergic nerve fibers in the intestine are extrinsic. 
Primary transmitter of sympathetic neurons. Inhibit motility in 
non-sphincter regions; contract the muscle of the sphincters; 
inhibit secretomotor reflexes, act as a vasoconstrictor neurons 
to the enteric arterioles. Separate neurons control each 
function. 
Serotonin Appears to participate in excitatory neuroneuronal 
transmission 
AMINO ACIDS  
Gamma-aminobutyric acid Present in different population of neurons, depending on 
species and region. Does not appear to be a primary 
transmitter 
PURINES  
ATP Probably contributes to transmission from enteric inhibitory 
muscle motor neurons 
PEPTIDES  
Substance P Present in intrinsic and extrinsic sensory neurons, intrinsic 
motor neurons. Excitatory transmitter to smooth muscle (co-
transmitter with Ach), may contribute to excitatory 
neuroneuronal transmission from enteric primary sensory 
neurons.  
VIP Excitatory transmitter of secretomotor neurons, contributes to 
transmission from enteric inhibitory motor neurons (co-
transmitter with NO), possibly a transmitter of enteric 
vasodilatator neurons. 
Galanin Present in secretomotor neurons and descending 
interneurons, in some inhibitory motor neurons. Roles 
unknown. 
Somatostatin No clearly defined role 
CGRP Present in some secretomotor neurons, interneurons, in axons 
of primary sensory neurons. Role unknown. 
Cholecystokinin Present in some secretomotor neurons and in some 
interneurons. May contribute to the excitatory transmission. 
Neuropeptide Y 
 
 
 
Present in secretomotor neurons; appears to inhibit secretion 
of water and electrolytes. Also present in interneurons and 
some inhibitory motor neurons. Probably not a primary 
transmitter 
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Neuromedin U 
 
 
A role as a transmitter is not established 
Opioids  
Enkephalin Present in interneurons and motor neurons. Probably provides 
feedback inhibition of transmitter release, prejunctional 
inhibition  
Dynorphin In secretomotor neurons, interneurons and some motor 
neurons. Does not appear a primary transmitter. 
Endorphins  
Peptide YY  
Pituitary adenyl cyclase-
activating peptide  
Localized predominantly in myenteric ganglia and smooth 
muscle 
Thyreotropin-releasing 
Hormone 
Vasoactive intestinal 
contractor (an endothelin) 
 
GASES  
Nitric oxide In inhibitory motor neurons (co-transmitter with VIP).  
Carbon monoxide 
 
 
 
modified from McConalogue and Furness, Coyal and Hirano 54; 86 
 
 
 
 
NEURONAL MARKERS 
 
Changes in the density of innervation can be observed when examined in full 
thickness biopsy specimens of the intestine. Apart from immunohistochemical 
techniques revealing a particular neurotransmitter or neuropeptide, it is useful 
to estimate changes involving the gut innervation as a whole. Classical 
histological methods, such as the silver staining 2 used to reveal neurons or 
nerve fibers are nonspecific and they involve treatments that are not 
compatible with immunohistochemical colocalization studies. A number of 
neural proteins, i.e. proteins originally isolated, or characterized, from nerve 
tissue, mainly brain, have been studied with respect to their putative exclusive 
presence in the enteric nervous system. Neurofilaments are neuron-specific 
intermediate filaments. They consist of three different polypeptide subunits and 
are an integral component of the cytoskeleton. However, not all neurons show 
neurofilament protein immunoreactivity 87. The presence of neurofilaments in 
the myenteric and submucous plexi has been reported, however mucosal 
nerves in the villi of the lamina propria are neurofilament protein-deficient both 
in animals 88 and human (Soinila, personal communication). S-100 protein, 
originally isolated from the brain, has been localized in the gut, in both 
Schwann cells and enteric glial cells 89. Extensive studies have revealed the 
presence of S-100 protein immunoreactivity in many non-nervous sites 6. 
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Growth-associated protein-43 
The 43 kD growth-associated protein (GAP-43) is an acidic membrane-bound 
phosphoprotein, expressed in conditions of embryonic growth, during axon 
regeneration and even at maturity in certain areas of the brain known to exhibit 
synaptic plasticity 90-93. GAP-43 induces process outgrowth from neurons 94. In 
the adult peripheral nervous system GAP-43 expression is generally low. 
However, expression of GAP-43 increases heavily after injury 95. Sprouting, 
uninjured neurons also express GAP-43 96. Moreover, denervation of motor 
endplates results in GAP-43 upregulation by terminal Schwann cells 97. GAP-
43 has been described in the rat stomach, and small and large intestine 8; 88; 98; 
99
. GAP-43-immunoreactive nerves have also been reported in the human 
small intestine and rectum 9; 69; 100. VIP has been found to co-localize with 
GAP-43 in the ferret ileum 9. In the rat jejunal villi, all electron microscopically 
identifiable nerve profiles were found to be GAP-43-positive 88. No further 
studies of co-localization of GAP-43 and neurotransmitters have been 
reported. 
 
Protein gene product 9.5 
Protein gene product (PGP) 9.5 is a cytoplasmic protein, specific for neurons 
and cells of the diffuse neuroendocrine system 5; 101-103. It has been used in 
various contexts to reveal nerve cells and fibers. It has been claimed to be 
sensitive neuronal marker, even better than NSE, in whole-mount preparations 
of mammalian intestine 104; 105. Comparison of GAP-43 and PGP 9.5 has 
shown that only a fraction of nerve fibers in normal adult pancreas exhibits 
GAP-43 immunoreactivity, whereas most if not all nerve fibers are PGP 9.5-
immunoreactive 106. Moreover, PGP 9.5- immunoreactive nerve fibers in the 
skin are more numerous than those revealed by GAP-43 107. GAP-43 and PGP 
9.5 have been reported to be equally sensitive markers of nerve fibers of the 
rat autonomic nervous system 8. 
 
Neuron specific enolase 
Enolase is an enzyme, necessary for anaerobic conversion of glucose to 
metabolites suitable for oxidation. The brain tissue contains a specific form of 
enolase that differs structurally, functionally and immunologically from the 
enolase present in other tissues 108. Neuron-specific enolase (NSE) is a 
common marker for both neurons and endocrine cells in the gut 4. It is also 
expressed by nonneuronal cells like the parafollicular cells of the thyroid gland, 
adrenal medullary chromaffin cells, glandular cells of the pituitary and the cells 
in the islets of Langerhans in the pancreas 108. Changes in NSE levels have 
been demonstrated in correlation with neuronal differentiation and in response 
to injury 6. 
 
 
Synaptophysin 
Synaptophysin is a structural component of synaptic and neuroendocrine 
vesicles and it has been used as a neuronal marker 7. 
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ULCERATIVE COLITIS AND ENTERIC NERVOUS SYSTEM 
 
Ulcerative colitis (UC) is an inflammatory disease of colon of unknown etiology 
19
. It occurs much more often in industrialized than in third-world countries. 
Men are slightly more likely to develop ulcerative colitis 109. Clinical symptoms 
are rectal bleeding, diarrhea, abdominal pain, and weight loss. The disease is 
acute or chronic with unpredictable relapses and remissions 110; 111. 
Microscopically, UC is primarily a mucosal disease. The traditional histological 
pathognomonic feature of UC is crypt abscess with accumulation of 
neutrophilic leukocytes in the lamina propria. Irregular villous mucosal surface, 
decrease in the mucus content, and distortion or atrophy of crypts support the 
diagnosis of UC. Severe form of UC includes destruction of glands and 
ulcerations. These histological changes can be apparent to some degree in UC 
even with normal appearing finding on endoscopy. Although there is no 
curative medical treatment, management of the disease remains primarily 
medical 112. However, surgery continues to have a major role in management 
of UC, because it may save the patient's life, eliminate the long-term risk of 
cancer 113, and abolish the disease. Surgery is indicated in UC either because 
of failure of medical treatment, or because of acute complications such as 
fulminant colitis, toxic megacolon, perforation, hemorrhage obstruction, or 
chronic complications such as risk of cancer, and extraintestinal manifestations 
114
. About 31%-45% of UC patients requires colectomy in the long run 115. 
 
In 1953 Storsteen, Kernohan and Bargen reported on 2-3-fold increase in the 
number of myenteric ganglion cells in UC 20. The precise mechanism for the 
hyperplasia remained obscure. Several studies have revealed changes in the 
neurotransmitter content of the gut, but a clearly defined profile of change has 
not emerged. Studies focused on sympathetic nerves have described an 
increase in catecholamine content of adrenergic nerves in UC 21. Substance P 
concentration is increased in inflamed colonic mucosa of UC patients 116; 117. 
Quantitative histochemical studies by our group and others have indicated that 
this change is mainly due to increased number of substance P-immunoreactive 
nerve fibers in the lamina propria 22; 25. Likewise, the number of substance P 
receptors is increased in UC colon 82; 118. Substance P immunoreactivity has 
also been reported to decrease in severe ulcerative colitis 22; 23. VIP-
immunoreactive nerves have been reported to decrease in ulcerative colitis 23; 
24
, however some authors have demonstrated no changes in the colonic 
content of VIP in patients with inflammatory bowel disease 119. 
 
In the rabbit and rat experimental colitis, ablation of sensory nerve fibers by 
chronic treatment with neurotoxin capsaicin significantly worsened the 
inflammation in acute colitis and subacute colitis 120; 121. Moreover, substance P 
receptor antagonist reduces the severity of colitis and has beneficial effects on 
the concomitant alterations of contractility 83.  
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POUCHITIS 
 
Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA), first 
described by Parks and Nicholls in 1978, has become an established surgical 
alternative for most patients with ulcerative colitis 122. In this operation all 
diseased mucosa is removed and furthermore transanal defecation and 
continence are preserved. The most frequent long-term complication of IPAA 
performed on UC patients is inflammation of the ileal reservoir, termed 
“pouchitis”. Pouchitis is a clinical syndrome of deterioration of IPAA function 
with diarrhea and acute inflammation and/or ulceration of the pouch, as 
assessed by endoscopy and biopsy histology. In our clinic, the cumulative risk 
of acute pouchitis and chronic pouchitis was 28% and 5.2%, respectively, at 11 
years after surgery 28. Even higher values of cumulative risk have been 
reported. In the Mayo clinic the cumulative risk of pouchitis at one, two, five 
and 10 years after surgery was 15 %, 23 %, 36 %, and 46 % respectively 27. 
 
The similarities in mucosal morphology between pouch ileum and UC colon 
and the action of the same inflammatory mediators in pouchitis and UC 
suggest that the pathogenesis of pouchitis and that of UC may be similar 123-
126
. This view is supported by the observation that pouchitis rarely develops in 
a reservoir constructed for reasons other than UC 123. The other suggested 
etiologies of pouchitis are stasis, nutritional deficiencies, ischemia or bacterial 
overgrowth 127. 
 
 
NITRIC OXIDE AND ULCERATIVE COLITIS 
 
Increased plasma nitrite levels have been measured in UC patients 128, but the 
precise etiology of this finding has remained obscure. Increased level of 
citrulline, the co-product of NO synthesis has been reported in the rectal biopsy 
of patients with ulcerative colitis 129. Furthermore, increased level of NO in 
luminal gas has been measured in the colon in patients with UC 130. Finally, 
NOS activity increases eightfold higher in the mucosa of UC colon than in 
control mucosa 131. As mentioned above, NOS-2-expression is induced in the 
epithelial cells of UC colon 26; 132-134. Contradictory results have been published 
on association of NOS-2 immunoreactivity with the degree of UC 26; 132; 134. 
There is some discrepancy as for NOS-2 immunoreactivity in the cells of 
lamina propria or submucosa in UC specimens 26; 132; 134. No reports about 
NOS-1 and NOS-3 concerning the UC are available. 
 
There is growing evidence that endogenous NO regulates mucosal barrier 
integrity under physiological conditions and counts for the increase in mucosal 
permeability associated with acute pathophysiological states 11; 135. NO may 
have protective functions in gut epithelium. These include the maintenance of 
blood flow, inhibition of platelet and leukocyte adhesion and/or aggregation 
within the vasculature, modulation of mast cell reactivity, and scavenging of 
reactive oxygen metabolites such as superoxide.  
 Review of the literature 
 
 
23
 
In active UC, excess production of superoxide and hydrogen peroxide is 
generated by activated leukocytes. These reactive oxidative metabolites and 
NO can produce peroxynitrite. Peroxynitrate can nitrate tyrosin and produce 3-
nitrotyrosine. The immunostaining of 3-nitrotyrosine localized in epithelial cells 
and in lamina propria 26; 132. However, a recent study failed to show 3-
nitrotyrosine immunoreactivity in epithelial cells, only in some cells in the 
lamina propria 134.  
 
The dilatation of colon in toxic megacolon syndrome has been attributed to NO 
136
. In an animal model of UC, NOS-2-deficient mice develop more severe 
experimental colitis and recover more slowly than wild type, NOS-2-expressing 
control animals 137. NOS inhibitor NG-nitro-L-arginine (L-NNA) aggravates the 
course of acetic acid-induced colitis in rats 138. Furthermore, NO-releasing 
derivative of mesalamine (5-ASA) enhances the anti-inflammatory effect of 
mesalamine in rats 139. In contrast, studies using inhibitors of NOS in 
experimental colitis would suggest that inhibition of NO production will reduce 
the intestinal inflammation and destruction 140; 141 
 
 
SMALL INTESTINAL ADAPTATION TO RESECTION 
 
Massive small bowel resection results in considerable morphological and 
functional changes in the remaining intestine 29,142,31; 143; 144. In the rat, mucosal 
surface and villous height increase, while disaccharidase and peptidase 
activities decrease. The remaining intestine also dilates, but no significant 
increase in its length occurs 29; 145; 146. Similar morphological adaptation has 
been reported in the dog and the rabbit. In contrast to the rat, resection-
induced lengthening of remaining intestine has been reported in the human 
and the pig 31; 147; 148. In resected piglets macroscopic adaptation (as measured 
by ileum length and circumference) appears to be completed in eight weeks 
after the operation, whereas the increase in the villous height is not observable 
until 14 weeks postoperatively 31. This adaptation increases the absorptive 
capacity of the remaining intestine and aims to maintain nutrient, fluid, and 
electrolyte balance. The adaptation involves hyperplasia of the mucosa with an 
increased number of microvilli and a net increase in the absorptive surface 
area.  
  
Luminal nutrition, humoral factors, and pancreaticobiliary secretions have been 
proposed as mediators of the adaptation 149; 150. These may stimulate the 
synthesis or release of enterotrophic regulatory peptides, such as the 
enteroglucagon family of peptides (glukagon like peptide-2) and gastrin and 
growth factors, such as epidermal growth factor and insulin-like growth factor-I 
149; 151-153
. Neural factors are also important. Vagotomy in pigs prevents 
adaptive increase in weight per unit length of residual intestine after resection 
and sympathectomy in rats decreases the cell proliferation and reduces 
mucosal mass 151.  
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Profound motor changes occur in the small intestinal remnant following 
extensive resection 154-157. One of these is prolongation of small intestinal 
transit time, the mechanism of which is poorly understood. Massive small 
bowel resection directly affects neuropeptide levels in the submucous plexus, 
resulting in an increased size of the VIP-immunoreactive neurons, while 
somatostatin -immunoreactive neurons remain unchanged 158. In contrast, VIP 
tissue concentration in the mucosa and the muscle layer decrease after 
massive small bowel resection, and somatostatin content remains constant 159. 
Moreover, CGRP content increases, and NPY content remains constant in 
muscle layer after resection 159. No quantitative estimation of neuropeptide-
containing nerves in resected gut has been reported. 
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AIMS OF THE STUDY 
 
The aim of this study was to examine how inflammation and adaptation change 
the expression of neurotransmitters in the enteric nervous system. Particular 
emphasis was put on the role of substance P and nitric oxide as mediators of 
neurogenic inflammation.  
 
Specific aims were 
  
1. to develop a quantitative morphometric method for evaluation of neuronal 
changes in tissue specimens of human gut.  
 
2. to study whether the changes caused by ulcerative colitis in the innervation 
of colon are specific for substance P;  
 
3. to study correlative changes in expression of neuronal, inducible, and 
endothelial NOS in ulcerative colitis; 
 
4. to study the correlation between the clinical degree of pouchitis and the 
expression of inducible and endothelial NOS in ileum reservoir; 
 
5. to study whether the changes observed after experimental short bowel 
adaptation can be explained by altered innervation. 
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SPECIMENS AND METHODS 
 
SPECIMENS 
 
Animals (V) 
Ten outbred female domestic pigs weighing between 19-25 kg were used for 
the experiment. Pigs were chosen as experimental animals because pig 
gastrointestinal anatomy and feeding habits resemble those of humans. 
 
All the animals received humane care in compliance with the Principles of 
Laboratory Animal Care and the Guide for the Care and Use of Laboratory 
Animals formulated and prepared by the Institute of Laboratory Animal 
Resources and published by the National Institutes of Health (NIH publication 
no. 86-23, revised 1985). The authorization to perform this study was given by 
the Provincial Government of Uusimaa in accordance to Finnish legislation. 
 
Massive small bowel resection was performed in five 3-month-old pigs (weight 
21-25 kg, mean ± SEM 23 ± 0.7 kg). The proximal resection was chosen 
because the ileum has more adaptive capacity than jejunum 30. The proximal 
75 % of the small bowel was resected from distal to the ligament of Treitz, so 
that the resected bowel included most of the jejunum and 50 % of the ileum. 
Bowel continuity was restored by end-to-end jejunoileal anastomoses using a 
one–layer seromuscular running stitch of 5-0 polyglyconate monofilament. 
During the operation, a whole-wall specimen was taken from the proximal part 
of the remaining ileum. The operated pigs and age-matched controls (N=5, 
weight 19-21 kg, mean ± SEM 19.4 ± 0.5 kg) were raised under standard 
conditions and allowed to eat ad libitum.  
 
After two months, whole wall specimens of the proximal part of the remaining 
ileum in both groups were obtained for histological and immunohistochemical 
studies. We also took specimens of the corresponding ileal segment of 5-
month-old unoperated pigs. Since no transsection-induced neuronal changes 
beyond 10 cm from the anastomosis have been reported 160 and since our 
specimens were taken 150 mm distally from the anastomosis, no sham 
operation was considered necessary. This strategy is supported by the 
following observations. The descending projections of the rat jejunal substance 
P-, VIP-, somatostatin-, and enkephalin-immunoreactive neurons are shorter 
than 8 mm, while galanin neurons have descending projections of 
approximately 20 mm in length 161. In the dog neuronal projections run for up to 
about 30mm. The ascending projections are even shorter. In the pig 
specifically, the enteric projections, with the exception of serotonergic fibers, do 
not extend for more than a few millimeters (Timmermans, personal 
communication). 
 
Human tissue specimens (I-IV) 
The study was carried out in the Gastrointestinal and Endocrinological 
Department of Surgery, Helsinki University Central Hospital during 1997-1999. 
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Oral or written informed consent was obtained from each patient before tissue 
sampling. The Ethics Committee of the Helsinki University Hospital has 
approved of the study protocol. (Table 2.). 
 
 
Table 2. Specimens  
Specimens Number of 
patients 
Study 
 
Whole wall gut: 
  
Normal colon 3 I 
 8 II 
 14 III 
Normal ileum 3 I 
UC colon 10 II 
 13 III 
 
Mucosal biopsies:   
UC ileum  8 IV 
Normal pouch 15 IV 
Chronic 
asymptomatic 
pouchitis 
 
 
8 
 
 
IV 
Chronic active 
pouchitis 
 
11 
 
IV 
Acute pouchitis 11 IV 
 
 
Whole-wall gut specimens 
Normal colon and ileum (I, II, III) 
Specimens of normal colon and ileum were taken from 24 adult patients 
undergoing resection of colon for treatment of colon or rectum neoplasia at 
Helsinki University Central Hospital during 1997-1999. The mean age of the 
patients was 66 years (range 38-83 years, 12 women and 12 men). None of 
the patients had bowel obstructions or any other colon disease. Whole-wall 
specimens were taken from the macroscopically normal margin of the resected 
colon or ileum.  
 
Ulcerative colitis (II, III) 
Several whole-wall specimens were taken from resected bowel of 19 patients 
with UC. The mean age of the patients was 37.7 years (range 22-77 years; 10 
women and 9 men). The specimens were taken from the least affected region 
of the colon and from the moderately affected colon. Some specimens were 
also taken from ulcerated regions with destroyed epithelium (II). In the study II 
the mean age of the patients was 31 years range 22-46 years; six women and 
four men. The patients were operated on for failed conservative treatment or 
for side effects of corticosteroids. One patient was operated on for moderate 
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dysplasia and primary sclerosing cholangitis. None of the patients were 
operated on for fulminant colitis. All patients received 5-amino-salicylic acid 
treatment orally; 8/10 patients received also oral corticosteroids. Besides the 
corticosteroid therapy, one patient received azathioprine. The mean duration of 
the disease was 7 years (range 1-15 years). In study III the mean age of the 
patients was 41 years (range 23-77 years, eight women and six men). The 
patients were operated on for failed conservative treatment or for side effects 
of corticosteroids. Eleven out of 14 patients received 5-aminosalicylic acid, 
13/14 received oral corticosteroids and one patient received azathioprine. 
Mean duration of the disease was 10 years (range 1-22 years). 
 
Mucosal biopsy specimens  
Mucosal biopsy specimens were taken from terminal ileum and ileum reservoir 
of UC patients (IV). Forty patients who had undergone restorative 
proctocolectomy with construction of ileal reservoir were included in this study. 
In all patients a two-limbed J-shaped ileal pouch had been constructed. The 
diagnosis of pouchitis was based on clinical, endoscopic and histological 
criteria. The main clinical symptom was an increase in defecation frequency 
with loose to watery stools. Abdominal cramping, bloody stools and systemic 
malaise were less common. In endoscopy, mucosal edema and erythema, 
contact bleeding, friability and ulcerations were typical for pouchitis. The 
histological findings in all specimens of pouchitis showed an increased number 
of neutrophils in the lamina propria and/or crypt abscesses and superficial 
erosions and atrophy of villi. 
 
The patients were divided in five groups: 
1. To obtain a control, biopsies were taken from normal terminal ileum of UC 
patients (N=8) during operation before reconstruction of the ileum reservoir. 
Examination by a pathologist revealed normal ileal histology.  
 
2. No pouchitis (N=15): Most patients were symptomless. If they had 
abdominal cramps or high frequency defecation, pouchitis was excluded by 
endoscopy. The endoscopic finding was normal pouch mucosa, and 
microscopically the finding mostly showed chronic inflammatory cell infiltration 
in the lamina propria. In some specimens, villus atrophy with colon metaplasia 
was found. Sometimes slight granulocyte infiltration was present without 
evidence of endoscopic signs of pouchitis or clinical symptoms of pouchitis. 
The time of endoscopy varied from 4 to 83 months after pouch reconstruction. 
 
3. Chronic asymptomatic pouchitis (N=8): This group includes patients who 
had had chronic relapsing inflammation in the pouch mucosa and received 
medication. At the time of the biopsy, the symptoms were largely decreased. 
However, the endoscopic finding revealed some small erosions in the mucosa, 
erythema or edema. In some patients the mucosa appeared quite normal. 
Upon histological examination, chronic inflammation was found and 
occasionally infiltration of neutrophils was observed. The time of endoscopy 
varied from 5 to 83 months after pouch reconstruction. 
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4. Chronic active pouchitis with exacerbated symptoms (N=11): This group 
showed the findings of acute pouchitis (see below). The patients had a history 
of three or more relapsing pouchitis episodes per year, or the symptoms 
worsened soon after finishing medication. The time of endoscopy varied from 
12 to 88 months after pouch reconstruction. 
 
5. Acute pouchitis (N=11): All the patients had symptoms of pouchitis and 
showed endoscopic and histological findings of acute inflammation. These 
patients did not have a history of chronic pouchitis. The time of endoscopy 
varied from 3 to 37 months after pouch reconstruction. 
 
Six biopsies from the each pouch were taken during sigmoidoscopy from the 
body of the pouch using a standard biopsy forceps. The suture or staple lines 
and visible ulcerations were avoided. 
 
Salivary gland specimens 
Oral surgeon took salivary gland specimens used for comparison for diagnostic 
purposes. The routine histological staining revealed normal gland morphology. 
 
 
METHODS 
 
Histology  
Sections of the whole wall specimens (I-III) were cut through formalin-fixed, 
paraffin–embedded tissue blocks and stained with Herovici-van Gieson 
method. The criteria of histopathological diagnosis were based on examination 
by a pathologist.  
 
In study IV, a pathologist unaware of the patient's clinical data examined the 
mucosal biopsy specimens for histological evaluation.  
 
The presence of active inflammation was recorded and scored 
semiquantitatively from 0 to 3 (0=absent, 1=mild, 2= moderate, 3= severe). The 
inflammation was recorded as active when conspicuous mucosal neutrophils or 
erosions were found. The villus atrophy was recorded and scored from 0 to 3 
(0= normal, high villus profiles, 1= low and deformed villus profiles, 2= focal 
few, deformed villus profiles 3= no villus profiles). 
 
 
Cytochemistry 
Preliminary studies were performed to find out the optimal fixation time and 
dilution for each staining.  
 
Specimens were immersed in 4% paraformaldehyde in phosphate–buffered 
saline (PBS), pH 7.2, for 8 hr (I-III), 2 hr (IV) or 24 hr (V) and then transferred 
into 20 % sucrose in PBS. The specimens were embedded in freezing gel and 
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10 µm cryostat sections were cut on chrome-alum-gelatin-coated glass slides. 
Specimens for NOS-3 immunostaining were frozen directly in liquid nitrogen 
and cryostat sections were immersed in 4 % paraformaldehyde in PBS for 15 
min. 
 
For immunohistochemistry the sections were incubated for 20 min with 5 % 
normal rabbit or swine serum at room temperature, and overnight with the 
primary antiserum diluted in PBS at +4°C. 
 
Staining detection was based on two different methods: indirect 
immunofluorescence or avidin-biotin-complex (ABC) method. After the primary 
incubation, the glasses were rinsed, incubated with secondary antibody for 1 h 
at room temperature. 
  
In indirect immunofluorescence method secondary antibodies were 
fluorescein-conjugated sheep anti-mouse IgG (1:300 in PBS, Jackson) for 
mouse-raised antibodies against GAP-43, synaptophysin, or NOS-1, and 
fluorescein-conjugated swine anti-rabbit (1:200 in PBS, Dako F205) for rabbit-
raised antibodies against VIP-, substance P, enkephalin, galanin, somatostatin, 
PGP 9.5, NSE, or NOS 1. After fluorescein staining method the preparation 
was stained with 0.05 % Pontamine Sky Blue for 10 min 162 to diminish 
background fluorescence (I, III). 
 
If ABC staining method (Vector ABC kit.) was used, endogenous peroxidase 
activity was blocked with 0.3% hydrogen peroxide in methanol for 5 min before 
the staining process (II, III, IV).  
 
Primary antibodies  
The sources and dilutions of the primary antibodies used are shown in Table 3. 
The antibodies against GAP-43, PGP 9.5, NSE and synaptophysin were 
examined as neuronal markers. Neuropeptide antibodies included those 
against VIP, substance P, somatostatin, enkephalin, galanin, and CGRP. For 
nitric oxide synthase histochemistry two different antibodies against NOS-1 
(neuronal NOS) and one for NOS-2 (inducible NOS) and one for NOS-3 
(endothelial NOS) were used.  
 Specimens and Methods 
 
 
31
 
Table 3. Primary antibodies 
Primary antibody Source Manufacturer Dilution Staining 
method 
Study 
VIP rabbit Incstar 1/500 IF I, V 
VIP rabbit Incstar 1/4000 ABC III 
Substance P rabbit Incstar 1/500 IF I, V 
Substance P rat Chemicon 1/100 ABC II 
Galanin rabbit Incstar 1/500 IF I, V 
Somatostatin rabbit Incstar 1/500 IF V 
Enkephalin rabbit Incstar 1/500 IF I, V 
CGRP rabbit Amersham 1/500 IF I, II, V 
GAP-43 mouse Boehringer 1/500 IF I 
    ABC II, III 
PGP 9.5 rabbit Affinity 1/2000 IF I 
NSE rabbit Sigma 1/1000 IF I 
   1/8000 ABC II 
Synaptophysin rabbit Sigma 1/500 IF I 
NOS-1 mouse Sigma 1/2000 ABC III 
NOS-1 rabbit Diasorin 1/8000 ABC, IF III 
NOS-2 rabbit Santa Cruz 
Biotechnology 
1/4000 ABC III, IV 
NOS-3 mouse Affinity 1/4000 ABC III, IV 
Incstar, Stillwater, MN, US; Diasorin, Stillwater, MN, US; Chemicon, Temecula, 
CA, US; Santa Cruz Biotechnology CA, US; Sigma, St. Louis, US; Amersham, 
Buckinghamshire UK; Affinity, Exeter, UK; Boehringer, Mannheim, Germany. 
 
 
Double staining 
For the double staining experiments, mouse anti-GAP-43 and rabbit-raised 
neuropeptide antibodies were incubated simultaneously, and the secondary 
antibodies consecutively. The second antibody for GAP-43 was fluorescein-
conjugated sheep anti-mouse IgG and for neuropeptide-antibodies was 
rhodamine-conjugated swine anti-rabbit IgG (1:100, DAKO R156) (I). 
 
 
Staining specificity 
For specificity controls, the primary antiserum was omitted from some sections, 
which resulted in negative staining. Neuropeptide immunoreactivity totally 
disappeared after preincubation with 0.1 µM or 1µM solution of the 
corresponding neuropeptide. The specificity of the following antibodies used in 
the present study has been characterized elsewhere: anti-substance P, batch 
104560 25 and anti-enkephalin, batch 935 163, anti-CGRP 164, anti-GAP-43, 
clone 91E12 91, anti-NSE, batch AB951 5, anti-synaptophysin, clone SVP-38 7. 
Based on the documentation provided by the manufacturer, PGP 9.5 
antiserum, batch Z00705, recognizes a 24kD band on Western blot 
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representing the PGP 9.5 peptide in lysates of whole rat brain and human 
neuroblastoma cell line. NOS-1 immunoreactivity totally disappeared after 
preincubation of the antiserum with 1µM solution of corresponding NOS-1 
peptide (Sigma, Diasorin). NOS-2 immunoreactivity totally disappeared after 
preincubation of the antiserum with 1 µM solution of NOS-2 peptide (Santa 
Cruz Biotechnology). For NOS-3 antibodies the corresponding peptide was not 
available. 
Double staining. The possibility of the secondary antibodies cross-reacting with 
each other was excluded by incubating the specimen first with one of the 
rabbit-raised antibodies followed by anti-mouse secondary antibody. 
Correspondingly, specimen stained with mouse-raised antibody was incubated 
with anti-rabbit secondary antibody. No labeling was observed in either case.  
 
 
Quantitation of immunoreactivity 
Immunoreactivity score 
One investigator who was unaware of the clinical and histological details 
performed the visual estimation of immunostaining of nerve fibers both in terms 
of the number and intensity. Immunoreactivity was graded from 0 to 3 (0 no 
reactivity, 1 sparse, 2 moderate, 3 dense/high immunoreactivity) (I, III, IV, V) 
 
Morphometry 
The specimens were examined by Leitz Aristoplan epi-illumination 
fluorescence microscope (I, III, V) or Leica DMLS microscope (II, III, IV) and 
photographed. The investigator was unaware of the clinical data of the 
specimen. Three or five sections were randomly selected and photographed 
(fluorescence) and the photographs were digitized either through a video 
camera and digitizing board (PC vision Plus, Image Technology) (V) or with 
Hewlett Packard Scanjet IIcx scanner (I). For some studies, randomly selected 
sections were digitized from light microscope under standardized 
circumstances through a video camera connected to the microscope, and 
digitizing board (II, III). The images were analyzed and stored in the computer 
using the Sigma Scan Pro 4.0 software (SPSS Science, Erkrath, Germany). 
 
The threshold values for different stainings were determined separately, and 
the same threshold value was used for all images stained for each particular 
antibody. After subtracting the background, an intensity histogram of this area 
was obtained and the threshold of significant intensity was determined by 
comparing the digitized image with the original view through the microscope or 
with the corresponding photomicrographs. The pixels representing values 
below the threshold value were electronically removed.  
 
Lamina propria. From sections containing longitudinal villous profiles, the area 
measured was determined by the epithelial basement membrane of the villus 
and the muscularis mucosae. In the study V, a value for specific neuropeptide 
immunoreactivity, referred to as the immunoreactivity index, was obtained by 
 Specimens and Methods 
 
 
33
summing the total number of pixels exceeding the threshold and by dividing 
this value by the area. This value takes into consideration all structures 
exhibiting specific immunoreactivity, regardless of their fluorescence intensity, 
and represents changes in the number of nerve fibers. Moreover, the intensity-
based immunoreactivity index was calculated (II, III, V) by multiplying each 
intensity value by the number of pixels exhibiting this intensity value. This value 
together with the immunoreactivity index can be used for estimation of changes 
in the fluorescence intensity of nerve fibers. 
 
Circular muscle layer. From the sections containing transverse sections of 
nerve fibers, three (II, III, V) or five (I) sections were randomly selected, and 
threshold values were determined as described above. In study V, the 
immunoreactivity index and the intensity based immunoreactivity index were 
calculated in the same way as in the lamina propria. To obtain an estimate of 
nerve fiber density (I, II, III), the number of nerve profiles per unit area and the 
total area represented by immunoreactive pixels in the measured area were 
determined. To obtain an estimate of the intensity of immunoreactivity, the total 
intensity, i.e. the sum of intensity values of all profiles exceeding the 
background was calculated for standard area of measurements. To obtain an 
estimate of the thickness of the nerve fibers, the mean perimeter of 
immunoreactive nerve fiber profiles was measured. For each profile, shape 
factor SF was calculated using the formula SF=4π×area/(perimeter)2. This 
parameter indicates how circular a profile is, the value for a circle being 1.0 and 
that of a line approaching 0. To exclude oblique sections, only those profiles 
were accepted the SF of which was 0.4 or greater. To exclude nonspecific 
fluorescent aggregates, profiles the area of which was under 4 pixels were 
omitted. Since some sections contained occasional profiles, which based on 
their size or shape were obviously not transected nerve fibers, it was decided 
to set an upper limit of 300 pixels for the profile area. The values obtained from 
the three sections of each specimen were averaged. 
 
Myenteric ganglia. One out of five sections of each specimen stained for NSE 
was selected and photographed under standardized conditions so that the 
whole ganglion chain profile of the section was included to obtain an estimate 
of ganglion volume. The photographs were digitized with Hewlett Packard 
Scanjet IIcx scanner. The total (cumulative) area of ganglion profiles in each 
section was calculated and the value was divided by the length of the ganglion 
chain. Average intensity of substance P immunoreactivity of randomly selected 
ganglion profiles was measured for each specimen (II). 
 
 
Statistics 
The results are expressed as the mean + the standard error of mean. ANOVA 
was used for statistical analysis when the possibility was examined whether the 
variance within one or more groups differs significantly from the variance of the 
whole material (II, III, IV). The Student's t-test (I, II, III, V) and Wilcoxon signed 
rank test (I) or Wilcoxon rank sum test with Bonferroni correction and Kruskall-
Wallis multiple comparison Z-value test (IV) were used for comparisons among 
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the groups. Linear -by-linear association test was also used in the study IV. 
The significance of the correlation between active inflammation score and 
NOS-2 immunoreactivity score was calculated by non-linear regression 
analysis (Kendall´s tau estimation). The calculations were made using Sigma 
Plot for Windows Version 4.0 (SPSS Inc., Germany) or Statexact 4 software 
(Cytel Inc., US) (IV). 
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RESULTS 
 
NEURONAL MARKERS IN MATURE HUMAN INTESTINE (I) 
 
GAP-43 
The distribution of GAP-43 was similar in the ileum and colon. In the mucosa 
GAP-43-immunoreactive nerve fibers were numerous. Nerve fibers extended 
up to the tips of the villi and formed a dense network at the base of the villus. 
Muscularis mucosae and the submucous layer also contained a network of 
individual GAP-43-immunoreactive fibers. The submucous layer also showed 
thick fiber bundles and ganglia containing a few neurons. In the muscle layer, 
GAP-43-immunoreactive nerve fibers were abundant and in both the circular 
and longitudinal layer their course was mostly parallel to that of the muscle 
fibers. The muscle cell membrane was nonreactive for GAP-43. In the ganglia, 
a network of GAP-43-immunoreactive fibers surrounded the neurons, 
particularly densely in the myenteric ganglia. Therefore, it was difficult to 
evaluate the intensity of the somatic immunoreactivity. However, the 
impression was that the neuronal somata lacked immunoreactivity (myenteric 
ganglia) or that the immunoreactivity was weak at the most (submucous 
ganglia). 
 
Co-localization of GAP-43 with neuropeptides 
Double labeling studies were carried out to assess the extent of coexistence of 
GAP-43 and the neuropeptides VIP, substance P, galanin, and enkephalin. 
GAP-43 partially co-localized in the nerve fibers with every neuropeptide 
studied. All VIP-, substance P, galanin and enkephalin-immunoreactive fibers 
also showed GAP-43 reactivity. However, GAP-43-immunoreactive fibers were 
found that lacked VIP, substance P, or galanin immunoreactivity. Ganglion cell 
bodies showing VIP, substance P, galanin, or enkephalin immunoreactivity 
lacked GAP-43 immunoreactivity. 
 
Comparison of synaptophysin, NSE, PGP 9.5 and GAP-43 
Lamina propria contained numerous thin synaptophysin- and NSE-
immunoreactive nerve fibers. Many cells in the villous core were weakly or 
moderately stained by both antibodies. Consecutive sections stained with PGP 
9.5 antibody revealed a greater number of reactive nerve fibers. GAP-43 
antiserum stained a dense network of nerve fibers but no cells. The number of 
stained nerve fibers per unit area was even greater than PGP 9.5-
immunoreactive fibers, and the fibers appeared more sharply demarcated. The 
distribution of GAP-43-, PGP 9.5 and NSE staining was similar in the 
muscularis mucosa. However this layer contained fewer synaptophysin-
immunoreactive fibers. All four stainings showed immunoreactive fibers around 
blood vessels. Likewise, all stainings revealed nerve fibers in the peripheral 
regions of the Payer's patches. 
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Morphometric analysis of GAP-43, PGP 9.5 and NSE immunoreactivities 
In the colon, the mean number of GAP-43-immunoreactive nerve profiles per 
unit area was 11 % higher than that of PGP 9.5- (p<0.05) and 33 % higher than 
that of NSE-immunoreactive fibers (p<0.01) The average number of pixels in a 
single profile was 52 % greater for GAP-43 than for PGP 9.5 (p<0.01) and 60 
% greater than for NSE (p<0.01). The mean perimeter of the GAP-43-
immunoreactive profiles was 24% greater than that of PGP 9.5 -(p<0.01) and 
27 % greater than that of NSE-immunoreactive fibers (p<0.01). The mean 
intensity of pixels in each profile was 6 % greater in the GAP-43-stained 
sections than in the PGP 9.5- (p<0.01) and 8 % greater than in the NSE- 
(p<0.01) stained sections. The mean total intensity of the GAP-immunoreactive 
profiles was 70 % greater than that of NSE-immunoreactive profiles (p<0.01) 
and 60 % greater than that of PGP 9.5-immunoreactive profiles (p<0.01). In the 
colon, there was no significant difference between the examined parameters of 
PGP 9.5 and NSE stainings. 
 
In the ileum, the mean number of GAP-43-immunoreactive profiles per unit 
area was 13 % higher than that of PGP 9.5- (p<0.05) and 121 % higher than 
that of NSE- immunoreactive fibers (p<0.001). The value for PGP 9.5 was 96 
% higher than that of NSE (p<0.001). The mean number of pixels in a single 
profile was 12 % higher for GAP-43 staining than for PGP 9.5 (ns) and 84 % 
higher than for NSE (p<0.001). The value of PGP 9.5 was 64 % higher than 
that of NSE (p<0.001). There was no significant difference in the value for the 
average intensity of pixels or for the perimeter between GAP-43 and PGP 9.5. 
For both GAP-43 and PGP 9.5 the values were significantly greater than that of 
NSE (p<0.01). The average total intensity of GAP-43-immunoreactive profiles 
was 13 % higher than that for PGP 9.5 (ns) and 105 % higher than that for 
NSE (p<0.001). The value for PGP 9.5 was 80% greater than that for NSE 
(p<0.001).  
 
NSE, PGP 9.5 and GAP-43 immunoreactivities in salivary glands 
For comparison, NSE, PGP 9.5 and GAP-43 immunoreactivities were also 
examined in the labial and submandibular salivary glands. Nerve fibers around 
the acini, tubuli, ducts and blood vessels showed immunoreactivity for all three 
antigens. The density of NSE-stained fibers was clearly lower than that of PGP 
9.5- or GAP-43-immunoreactive ones, which revealed a very rich network of 
fibers throughout the gland. No essential difference was observed between 
PGP 9.5 and GAP-43 staining. 
 
 
CHANGES IN THE MORHOLOGY OF ENTERIC NERVOUS SYSTEM IN UC 
COLON (II) 
 
The distribution of GAP-43-immunoreactive fibers in the lamina propria of least 
and moderately affected regions of UC colon was similar to that in the normal 
colon. However, the very severely affected lesions, which contained only 
destroyed villous profiles or no villi at all, showed very few fragmented or no 
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GAP-43-immunoreactive fibers. The staining also revealed numerous GAP-43-
immunoreactive fibers in the thickened muscularis mucosae. In the circular 
muscle layer, the GAP-43 -immunoreactive fibers seemed to be more 
numerous in moderately affected region of colon than in normal colon or in 
least affected colon. In the ganglia, no essential differences in GAP-43 
immunoreactivity between normal colon and UC colon were observed. 
 
Neuropeptide-containing nerve fibers in UC colon 
Distribution of substance P, VIP, CGRP, somatostatin, enkephalin and galanin 
in normal and UC colon specimens was estimated by visual examination. 
Substance P immunoreactivity was increased in UC colon, while no difference 
between control and UC colon was observed for the other peptides. Therefore, 
the following analysis was limited to substance P. 
Substance P 
In normal colon, some thin varicose substance P-immunoreactive fibers were 
found in the lamina propria. The fibers extended through the villus. Some fibers 
in the muscularis mucosae were immunoreactive for substance P. In the 
submucosa, some thick substance P-immunoreactive fiber bundles, and also 
some thin substance P-immunoreactive fibers around blood vessels were 
revealed. Several small submucous ganglia contained substance P-
immunoreactive neurons. Both muscle layers contained thin substance P-
immunoreactive nerve fibers. The myenteric plexus contained some substance 
P -immunoreactive neurons and quite many substance P-immunoreactive 
fibers. 
 
Least affected region of UC colon. On visual estimation, the number of 
substance P-immunoreactive fibers in the lamina propria was greater in 
ulcerative colitis than that in normal colon. In the muscularis mucosae, 
submucosa, muscle layer, and in the submucous and myenteric ganglia, the 
distribution of substance P immunoreactivity was similar to that of normal colon 
 
Moderately affected region of UC colon. The number of substance P-
immunoreactive nerve fibers in the lamina propria was markedly increased, as 
compared to the two other groups. The intensity of nerve fibers seemed also to 
be higher. The thickened muscularis mucosae contained many fragmented 
fibers. Distribution of substance P immunoreactivity in the submucous and 
muscle layer, and in the submucous and myenteric ganglia was similar to that 
in the other two groups.  
 
Quantitative measurements  
GAP-43 
In the lamina propria, the total intensity of GAP-43-immunoreactivity was 4.79 ± 
0.99 (arbitrary units) in normal colon, 4.64 ± 0.78 in least affected UC colon 
and 5.26 ± 0.90 in moderately affected UC colon. The total area of GAP-43 
immunoreactivity was 64 ± 12 in normal colon, 60 ± 8 in least affected UC 
colon, and 68 ± 1 in moderately affected UC colon. There were no significant 
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differences between the groups. In the circular muscle layer there were no 
significant differences in the measured parameters between normal colon and 
UC colon (Table 4). 
 
 
Table 4. Quantitation of substance P and GAP-43 immunoreactivities  
Group Normal colon Least affected  
UC 
Moderately  
 affected UC 
 
Lamina propria     
 
GAP-43 
    
 
Total area 64±12 60±8 68±1 ns  
Total intensity 4.79±0.78 4.64±0.78 5.29±0.90 ns  
Substance P     
 
Total area 8±2 17±5 30±4 §  ***  
Total intensity 
 
0.55±0.15 1.30±0.35 2.22±0.28 §  ***  
Circular muscle     
 
GAP-43     
 
Number of nerve 
fibers 
102±9 99±10 133±18 ns  
Total area 164.5±34.7 149±25.1 182.7±30.1 ns  
Total intensity 2691±592 2428±428 2945±503 ns  
Perimeter of a 
nerve fiber 
14.4±1.3 14.3±1.2 13.6±0.9 ns  
Substance P     
 
Number of nerve 
fibers 
17±2 15±3 25±6 ns  
Total area 9.68±1.53 9.16±2.98 11.85±2.77 ns  
Total intensity 134±22 128±44 157±38 ns  
Perimeter of a 
nerve fiber 
8.1±0.6 8.1±0.5 7.3±0.5 ns  
Mean ± SEM, Student's t-test. §   p<0.05 comparison with least affected and 
moderately affected UC colon, *** p<0.001 comparison with normal colon and 
moderately affected UC colon. 
 
Substance P 
In the lamina propria, total intensity of substance P-immunoreactive nerve 
fibers was 0.55 ± 0.15 in the normal colon, 1.30 ± 0.35 in least affected UC 
colon (p=0.087) and 2.22 ± 0.28 in moderately affected UC colon (p<0.001). 
The value for least affected UC colon and that for moderately affected UC 
colon are 136 % and 304 % higher than the control value. The value for 
moderately affected UC colon is 71 % higher than that for least affected UC 
colon. Total area of substance P immunoreactive nerve fibers was 8 ± 2 in the 
normal colon, 17 ± 5 in least affected UC colon (p=0.12), and 30 ± 4 in 
moderately affected UC colon (p<0.001). The difference between least affected 
and moderately affected UC colon was significant (p<0.05). The area and total 
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intensity of substance P immunoreactivity correlated with the degree of UC 
(Spearman´s correlation test p<0.001). Comparison of several parameters in 
the circular muscle layer revealed no significant differences for substance P 
immunoreactivity between normal colon and UC colon (Table 4). 
 
Myenteric ganglia 
The average intensity of substance P immunoreactivity in myenteric ganglia 
was 75.8 ± 1.5 in normal colon, 78.1 ± 1.2 in least affected colon, and 77.1 ± 
1.2 in moderately affected colon. The differences between the groups are 
nonsignificant. The average cumulative area of NSE-immunoreactive profile of 
the myenteric ganglia per unit length of the plexus was 1.39 ± 0.21 in normal 
colon, 1.86 ± 0.17 in least affected colon, and 1.88 ± 0.15 in moderately 
affected colon. The differences between the groups were nonsignificant. 
 
 
NITRIC OXIDE SYNTHASES IN NORMAL HUMAN COLON AND UC COLON 
(III) 
 
NOS-1 immunoreactivity  
The epithelium and most of lamina propria lacked NOS-1 immunoreactivity. 
Muscularis mucosae contained a loose plexus of thin, varicose NOS-1-
immunoreactive fibers, which occasionally extended a short distance into the 
lamina propria. Numerous small ganglia in the superficial part of submucosa 
formed the submucous plexus. It contained a loose NOS-1-immunoreactive 
fiber plexus, which was continuous with that of the muscularis mucosae. The 
submucous ganglion neurons were surrounded by NOS-1-immunoreactive 
terminals but the neurons themselves were nonreactive for NOS-1 with the 
exception of solitary cells sporadically found in few specimens. Conspicuously, 
no convincing observation on NOS-1-immunoreactive perivascular innervation 
was made. The deeper layer of submucosa was devoid of NOS-1-
immunoreactive fiber network, although it showed some thicker NOS-1-
immunoreactive fiber bundles. The inner, circular muscle layer contained rich 
NOS-1-immunoreactive innervation, which was mostly visualized as cross-
sections of nerve fibers. Occasionally, solitary NOS-1-immunoreactive neurons 
were observed among the muscle fibers. The outer, longitudinal muscle layer 
showed only few NOS-1-immunoreactive fibers, which showed as solitary, 
longitudinal fiber profiles. The myenteric plexus contained bundles of NOS-1-
immunoreactive fibers and basket-like NOS-1-immunoreactive terminal 
networks densely covered the ganglion neurons. Most myenteric ganglion 
neurons were nonreactive. The number of NOS-1-immunoreactive neurons per 
ganglion profile varied greatly: some contained none, in some a maximum of 
about one third of the neurons were reactive. An overall estimate was obtained 
that approximately 10 % of the myenteric ganglion neurons showed NOS-1 
immunoreactivity.  
 
As in controls, lamina propria lacked NOS-1 immunoreactivity in UC colon. In 
muscularis mucosae of least affected UC specimens, many areas lacked NOS-
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1 immunoreactive nerve fibers completely, although in some places few solitary 
NOS-1 immunoreactive fibers were observed. In moderately affected UC, the 
reduction was even more conspicuous. NOS-1 staining in the submucosa was 
indistinguishable from the controls. Likewise, no difference from the control 
was apparent in NOS-1 immunoreactivity of the muscle layers. The visual 
impression was confirmed by quantitative morphometric analysis, which 
revealed no significant differences in the total area or intensity of 
immunoreactive fiber profiles, fiber thickness or the number of fibers per unit 
area. 
 
Since NOS and VIP immunoreactivities colocalize in at least some enteric 
neurons and nerve fibers, it was of interest to study whether the reduction in 
the number of NOS-1-immunoreactive fibers in the muscularis mucosae 
correlated with a similar change in VIP-immunoreactivity. However, no obvious 
difference in the density of VIP-immunoreactive nerve fibers in the muscularis 
mucosae between control and UC specimens was observed. 
 
NOS-2 immunoreactivity 
Half the specimens of normal colon completely lacked NOS-2 
immunoreactivity, and the other half contained vague epithelial NOS-2 
immunoreactivity deep in some crypts. Some least affected UC specimens 
were completely nonreactive for NOS-2, while in others, local NOS-2-
immunoreactivity was observed in some villus tips and in some crypts. In 
moderately affected UC, uniform epithelial NOS-2 immunoreactivity was 
consistently seen in the surface epithelium and in the crypts. The reactivity was 
intense in the apical region of epithelium, while only weak reactivity was seen 
in the rest of the epithelium. Occasionally cells exhibiting varying NOS-2 
staining intensity were seen in the mucosa and submucosa. However, some 
stained cells were also seen in specimens incubated with antiserum 
preabsorbed with NOS-2 peptide. Although the possibility cannot be excluded 
that some specifically NOS-2-reactive cells may be present, their number is 
very low at any rate. 
 
NOS-3 immunoreactivity  
In normal colon, NOS-3 antiserum stained exclusively vascular profiles, the gut 
epithelium being nonreactive. Blood vessels in the lamina propria showed 
uniformly strong NOS-3 immunoreactivity and they extended throughout the 
villous core. The submucosa also contained numerous NOS-3-stained blood 
vessel profiles of greatly varying size. Staining intensity in most vessels was 
weak to moderate, while some intensely stained profiles were also present. 
The difference in vascular staining intensity between the lamina propria and 
submucosa was consistent in all specimens. In the muscle layers, the number 
of vascular profiles per unit area, as estimated visually, was clearly lower than 
that in the submucosa, there being no essential difference between the inner 
and outer muscle layers. Submucous and myenteric ganglion neurons were 
nonreactive.  
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In specimens of least affected region of UC, the villi were often thickened. 
However, the distribution and intensity of NOS-3 immunoreactivity and the 
density of vascular profiles in lamina propria as well as in the other layers were 
essentially similar to those of normal colon. In 4 out of 5 specimens the 
difference in staining intensity between lamina propria and submucosa was 
clearly observed. In moderately affected UC, marked villus atrophy was evident 
and the number of NOS-3-immunoreactive profiles was in many areas 
increased. In 4 out of 5 specimens, the vascular staining intensity in the lamina 
propria was lower than that in control and in 3 out of 5 specimens no difference 
in staining intensity between lamina propria and submucosa of the same 
specimen could be seen. NOS-3 immunoreactivity in the muscle layers was 
similar to that in controls. As in controls, the submucous and myenteric 
ganglion neurons were nonreactive. 
 
 
NITRIC OXIDE SYNTHASES IN TERMINAL ILEUM AND IN CONTINENT 
ILEUM RESERVOIR OF UC PATIENTS (IV) 
 
NOS-1 immunoreactivity 
Biopsies taken revealed only mucosal structure limited to the upper portion of 
muscularis mucosae. No NOS-1-immunoreactivity fibers were found in the 
lamina propria. Thus, no ganglia were included in the biopsy specimens. 
 
NOS-2 immunoreactivity 
In 6 out of 8 specimens of normal terminal ileum, no NOS-2 immunoreactivity 
was observed. Two specimens showed an occasional villous profile with some 
reactivity in the villus epithelium. In no-pouchitis group, several specimens 
displayed no NOS-2 reactivity at all, while in others some villi or crypts with 
NOS-2 immunoreactive epithelium were seen. In asymptomatic chronic 
pouchitis group, some specimens showed no NOS-2 immunoreactivity, while in 
most specimens areas of NOS-2 immunoreactive epithelium were consistently 
observed. In active chronic pouchitis group, only one specimen lacked NOS-2 
immunoreactivity, all others regularly showed moderate to extensive epithelial 
NOS-2 staining. Acute pouchitis group showed NOS-2 staining pattern similar 
to that of active chronic pouchitis, there being unexceptionally moderate or 
abundant epithelial NOS-2 staining. 
 
NOS-2 immunoreactivity was almost exclusively confined to the epithelium. 
With respect to a single epithelial cell, the staining was localized in the apical 
cytoplasm, while the basal cytoplasm showed only vague reactivity. Only few 
solitary NOS-2 immunoreactive cells were observed in the lamina propria or 
submucosa in groups with pouch. No immunoreactive cells were found in the 
terminal ileum group. No staining was observed in the nerve fibers or in the 
endothelium in any group.  
 
  Results  
42 
Semiquantitative analysis  
The value of NOS-2 immunoreactivity was 0.25 ± 0.16 in normal ileum of UC 
patients, 0.67 ± 0.19 in no pouchitis group, 1.19 ± 0.40 in chronic 
asymptomatic pouchitis group, 2.0 ± 0.23 in chronic active, and 2.18 ± 0.12 in 
acute pouchitis group. 
 
The values of no-pouchitis group and chronic asymptomatic pouchitis did not 
differ significantly from normal ileum. The values of both normal ileum and no 
pouchitis group differed significantly from the values of chronic active and 
acute pouchitis groups (p<0.0005).  
 
NOS-3 immunoreactivity  
NOS-3 immunoreactivity was confined to the vascular endothelium and no 
staining was seen in the villus or gland epithelium in any groups. In terminal 
ileum specimens, as well as in no-pouchitis specimens, NOS-3-
immunoreactive vascular profiles were readily observed in the lamina propria 
and at the base of the villi. However, NOS-3-reactive profiles were only rarely 
observed in the villus core. By visual examination, chronic asymptomatic, 
chronic active and acute pouchitis groups showed a greater density of vascular 
profiles in the lamina propria than the no-pouchitis group. In the pouchitis 
groups, NOS-3 staining revealed immunoreactive vessels throughout the villus 
core. No essential difference in the intensity of immunoreaction was observed 
between the groups. 
 
 
ACUTE INFLAMMATION AND VILLUS ATROPHY SCORES (IV) 
 
Acute inflammation score in normal ileum was consistently 0, in no pouchitis-
group, 0.53 ± 0.17, in chronic asymptomatic pouchitis group 1.00 ± 0.33, in 
chronic active pouchitis group 1.80 ± 0.20 and in acute pouchitis 1.64 ± 0.15. 
The values for all three pouchitis groups differed significantly from that of the 
normal ileum (p<0.05, p<0.0005, and p<0.0005, respectively). The value for no 
pouchitis group did not differ from that of the chronic asymptomatic pouchitis 
group, but did differ from those of chronic active and acute pouchitis groups 
(p<0.0005 and p<0.001, respectively). 
 
Both NOS-2 immunoreactivity score, acute inflammation score and villus 
atrophy score showed a significant correlation to the clinical degree of pouchitis 
(Linear-by-linear association test, p<0.01, p<0.0001 and p<0.0005, 
respectively). 
 
NOS-2 immunoreactivity score significantly correlated with the acute 
inflammation score (p < 0.0001, Kendall´s tau estimate 0.654, 95% confidence 
interval 0.521, 0.790). 
 
In all pouchitis groups marked villus atrophy was found and the scores 
significantly differed from those of both normal ileum (p<0.01, p<0.01 and 
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p<0.005 respectively) and no-pouchitis group (p<0.05, p<0.05 and p<0.005 
respectively). 
 
 
EFFECTS OF MASSIVE PROXIMAL SMALL BOWEL RESECTION IN THE 
PIG (V) 
 
Two months after the resection the 5-month-old pigs in the resection group 
weighed 36-54 kg (46 ± 3.1 kg), and those in the unoperated group 70-74 kg 
(72 ± 0.7 kg) (p<0.01). The increase in weight was 23 ± 2.7 kg in the resected 
group and 52 ± 0.7 kg in unoperated group (p<0.001). 
 
VIP 
In 3-month-old control pigs numerous VIP-containing nerve fibers were 
observed in the lamina propria. They extended throughout the core of the 
villus. Moderate numbers of fibers were seen in the muscularis mucosae, 
submucosa, and smooth muscle. VIP-immunoreactive cell bodies were found 
in submucosal and myenteric plexuses. In 5-month-old unoperated pigs the 
staining of VIP fibers was similar to that in the 3-month-old pigs. In 5-month-old 
operated pigs VIP-immunoreactive fibers were not as numerous as in 3-or 5-
month-old unoperated pigs. In the circular muscle layer, the VIP 
immunoreactivity index was 1.989 ± 0.108 in the 3-month-old pigs, 1.730 ± 
0.115 in the 5-month-old unoperated pigs and 0.0882 ± 0.288 in 5-month-old 
operated pigs. The change was significant in relation to both unoperated 
control groups (p< 0.01). In the villus, the VIP immunoreactivity index was 
4.372 ± 0.605 in 3-month-old pigs, 3.929 ± 0.407 in 5-month-old pigs and 
2.535 ± 0.264 in 5-month-old operated pigs. When the 5-month-old operated 
piglets were compared to 5-month-old unoperated piglets or to 3-month-old 
unoperated piglets, the difference in the immunoreactivity of villi was significant 
(p<0.05). Changes in the intensity- based immunoreactivity of the circular 
muscle layer and villi were similar to those in the immunoreactivity index. 
 
Galanin 
The distribution of galanin immunoreactivity was similar to that of VIP. The 
number of galanin immunoreactive fibers was not as great as that of VIP-
immunoreactive fibers. As was the case for VIP, fewer galanin-immunoreactive 
fibers were seen in the specimens of 5-month-old operated pigs than in the 
controls. The galanin immunoreactivity index of circular muscle layer was 1.204 
± 0.199 in the 3-month-old pigs, 1.402 ± 0.137 in the 5-month-old pigs and 
0.423 ± 0.238 in the 5-month-old operated pigs. There was no difference 
between 3- and 5-month-old unoperated pigs, but the operation caused a 
marked reduction of the galanin immunoreactivity index (p< 0.05). In the 
immunoreactivity of the villi, we could not measure any significant differences 
between the groups. Changes in the intensity-based immunoreactivity were 
similar to those in the immunoreactivity index. 
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Enkephalin 
In 3-month-old pigs, many enkephalin-immunoreactive fibers were seen in the 
circular muscle and in the myenteric plexus. The mucosa, submucosa and 
longitudinal muscle did not contain any fibers, nor could we see any reactive 
cell bodies. In the 5-month-old pigs, both unoperated and operated, the 
distribution of enkephalin-immunoreactive fibers was similar to that in 3-month-
old pigs. The enkephalin immunoreactivity index was 0.632 ± 0.107 in 3-month-
old pigs, 1.306 ± 0.215 in 5-month-old control pigs (p<0.05 as tested against 3-
month-old controls), and 0.449 ± 0.106 in the 5-month-old operated pigs 
(p<0.05 as tested against both 5-month-old and 3-month-old control pigs). 
Changes in the intensity-based immunoreactivity were similar to those in the 
immunoreactivity index. 
 
Substance P 
Substance P containing nerve fibers were detected in all layers of the intestine 
and also in the ganglia. There were a few fibers in the lamina propria, 
submucosa and in the longitudinal muscle. The number of fibers was moderate 
in the circular muscle and the myenteric plexus. Visually we observed no 
difference between these three groups. Therefore no quantitation was 
attempted. 
 
Somatostatin 
We observed somatostatin-containing nerve fibers in both the submucous and 
myenteric plexuses. Both submucosal and myenteric ganglia contained 
somatostatin-immunoreactive cell bodies. No differences were observed 
between the three groups. 
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DISCUSSION 
 
 
GAP-43 IS A SUPERIOR NEURONAL MARKER IN HUMAN MATURE 
INTESTINE 
 
GAP-43 is known as a neuronal membrane-bound protein associated with 
development and regeneration. Moreover, it is continuously expressed in 
certain regions of the mature brain 165; 166, as well as in the autonomic nervous 
system 8. It has remained unknown whether GAP-43 immunoreactivity 
correlates with particular neurotransmitters or neuropeptides. The present 
study demonstrates abundant GAP-43-immuoreactive nerve fibers in the 
normal human small and large intestine. In previous studies, GAP-43 
immunoreactivity has been described in the rat stomach, and small and large 
intestine 8; 88; 98; 99. GAP-43-immunoreactive nerves have also been reported in 
the human small intestine and rectum 9; 69; 100. All these studies unanimously 
report on a dense network of GAP-43-immunoreactive nerve fibers in all gut 
layers. In the present study, the distribution of GAP-43-immunoreactive fibers 
in the normal human colon was similar to that in the small intestine. 
Colocalization studies showed that all VIP-, substance P-, galanin- and 
enkephalin-containing nerve fibers also showed GAP-43 immunoreactivity. 
Previously VIP has been found to colocalize with GAP-43 in the ferret ileum 9. 
In the rat jejunal villi, all electron microscopically identifiable nerve profiles were 
found to be GAP-43 positive 88. Taken together, these observations suggest 
that GAP-43 is a universal neuronal marker in the mature enteric nervous 
system.  
 
Submucous ganglion neurons lacked GAP-43 immunoreactivity and myenteric 
neurons displayed only very weak GAP-43 immunoreactivity. Stewart and 
coworkers (1992)8 found no GAP-43 immunoreactivity in the rat enteric 
ganglia. Sharkey and coworkers (1990)9 found weak immunoreaction in the 
ganglion cells in the rat myenteric plexus and also in the neurons in the 
submucous plexus in the human duodenum. They also demonstrated by in situ 
hybridization technique that enteric neurons express GAP-43-mRNA. These 
results indicate that mature enteric neurons synthesize GAP-43, albeit at low 
levels.  
 
 
COMPARISON OF GAP-43 WITH PGP 9.5 AND NSE  
 
GAP-43 as a neuronal marker has not been compared in the gut with other 
established neuronal markers, such as PGP 9.5 or NSE. PGP 9.5 is a 
cytoplasmic protein localized both in the central and peripheral neurons and 
nerves 5; 101-103. It has been claimed to be a sensitive immunohistochemical 
neuronal marker, even better than NSE, for the enteric nervous system in 
whole mount preparations of mammalian intestine 104; 105. In the present study 
visual investigation indicated that GAP-43 reveals a slightly denser nerve fiber 
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network than PGP 9.5 both in lamina propria and in the muscle layer. The 
GAP-43-immunoreactive fiber profiles showed greater intensity were thicker 
and sharper demarcated than those stained with PGP 9.5 antiserum. Better 
visibility of GAP-43-immunoreactive nerves is likely due not only to greater 
immunofluorescence intensity per se, but also to different intracellular 
distribution of the two proteins, GAP-43 being membrane-bound while PGP 9.5 
is soluble. An additional factor contributing to the appearance of GAP-43-
immunoreactive fibers is immunoreactivity of satellite cells or non-myelinating 
Schwann cells around enteric nerve fibers. This possibility is based on the 
observation both in vitro and in vivo that rat glial cells and non-myelinating 
Schwann cells express GAP-43 167.  
 
Comparison of GAP-43 and PGP 9.5 has shown that only a fraction of nerve 
fibers in normal adult pancreas exhibits GAP-43 immunoreactivity, while most if 
not all nerve fibers are PGP 9.5-immunoreactive 168. Likewise, PGP 9.5-
immunoreactive nerve fibers in the skin are more numerous than those 
revealed by GAP-43 107. This is in agreement with the original concept that 
GAP-43 is associated with developing or regenerating nerves. However, it 
contrasts with our observation on the human salivary glands in which GAP-43 
immunostaining revealed a somewhat denser plexus of nerve fibers than PGP 
9.5, as well as with those reported on the rat autonomic nervous system in 
which GAP-43 and PGP 9.5 are equally sensitive markers of nerve fibers 8.  
 
NSE is a widely used neuronal marker, although several neuroendocrine and 
non-neuronal cells also express it 108. Our observation was similar to that 
reported previously 4 in showing a NSE-immunoreactive fiber network 
throughout the lamina propria and muscle layer. However, NSE-
immunoreactive profiles were thinner and less numerous than those stained 
with GAP-43 or PGP 9.5. Nonspecific staining of connective tissue cells in the 
lamina propria further hindered the visibility of NSE-immunoreactive nerve 
fibers. No nonspecific staining was seen in the muscle layer. Nevertheless, 
fewer and less intensively stained nerve fibers were revealed with NSE staining 
as compared with GAP-43 or PGP 9.5 stainings.  
 
In contrast to nerve fiber staining, NSE was a superior marker of ganglion 
neurons. All ganglion neurons showed a strong cytoplasmic immunoreactivity. 
Somatic PGP 9.5 immunoreactivity varied in intensity and GAP-43 revealed 
only vaguely reactive neuronal somata at the most. Poor staining by GAP-43 
antibody is likely due to rapid transportation of the protein into the axons to be 
incorporated into the axolemma.  
 
Quantitative analysis of the nerve fibers in the circular muscle layer verified our 
visual observations as for the order of sensitivity of the three markers: GAP-
43>PGP 9.5>NSE. Both in the colon and ileum, GAP-43 revealed over 10 % 
more nerve fibers per unit area than the other two markers, indicating that 
GAP-43 staining reveals fibers unstained by PGP 9.5 antiserum. The 
difference in average number of pixels per single profile, a parameter 
correlating with profile size, was significant in the colon, and the trend was 
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similar in the ileum. Similar result was obtained when average profile 
perimeters were compared. These results suggest that the fibers revealed by 
GAP-43 staining are thicker than those stained by the PGP 9.5 or NSE 
antibodies. Total intensity, as defined in the present study, sums the intensity 
values of each pixel in a profile, and is thus sensitive to changes in profile size 
and/or intensity. Therefore, the difference in total intensity of a single profile 
between GAP-43-immunoreactive and the other two markers is expected and 
can be explained by the differences in the number of pixels per profile. In fact, 
the values for average intensity of profiles were essentially similar for each 
antibody, the difference between GAP-43 and the other two being only about 
1/10 of the difference in total intensity values. In summary, our results suggest 
that GAP-43 immunoreactivity reveals more numerous and thicker nerve fibers 
than PGP 9.5 or NSE immunoreactivities although the true staining intensity is 
essentially similar for the three markers. In contrast, NSE is a superior marker 
for neuronal somata.  
 
 
INCREASE IN NERVE DENSITY IN UC INVOLVES EXCLUSIVELY 
SUBSTANCE P CONTAINING NERVE TERMINALS 
 
This study confirmed the previous results that the density of substance P-
immunoreactive fibers in colonic mucosa increases in UC 22; 25. The increase in 
substance P immunoreactivity was proportional to the degree of inflammation, 
when control specimens and least and moderately affected UC specimens 
were compared. In consecutive sections stained for GAP-43, no corresponding 
differences were observed. Since GAP-43 is a general neuronal marker in the 
human gut, this comparison suggests that the increase in nerve density is 
specific for substance P-containing nerve fibers. This conclusion is in 
accordance with published literature on neuropeptide changes in UC, lacking 
reports on increased density for any other peptide than substance P 22-25. In 
preliminary studies, we screened the neuropeptides VIP, galanin, somatostatin 
and CGRP, without observing any increase in their innervation pattern. The 
density of GAP-43-immunoreactive nerve fibers remaining unchanged in 
control and UC specimens supports the conclusion that the increase in 
substance P fibers is not explained by tissue shrinkage caused by UC. 
 
The density of substance P-immunoreactive nerve fibers decreases in severe 
UC 22; 23. Similar change occurs in VIP-immunoreactive nerves 23; 24. This is in 
line with the present observation on lack of substance P-immunoreactive 
nerves in severely affected UC specimens. Lack of substance P-containing 
nerves correlated with subtotal disappearance of GAP-43-immunoreactive 
nerves. Taken together, these findings suggest that disappearance or strong 
decrease in neuropeptide-containing nerves in severe UC is simply due to 
complete destruction of innervation at the extreme stage of the disease.  
 
The density of nerve fibers in the lamina propria remained unchanged in mild 
and moderate degree of UC, as illustrated by constant GAP-43 
immunoreactivity. This confirmed that the nerve fibers of enteric nervous 
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system do not proliferate in mild and moderate UC. Thus, the increase in 
substance P immunoreactivity in the lamina propria seems to be caused by 
increased synthesis of substance P, so that more substance P-immunoreactive 
fibers become visible.  
 
Several parameters describing the innervation of the circular muscle layer, 
such as the density and thickness of substance P-immunoreactive nerves, or 
intensity of the immunoreaction remained unchanged in mild, moderate or 
even severe UC as compared to controls. The number of substance P-
containing nerves of the circular muscle is not affected by extrinsic denervation 
161; 169-171
, indicating that these nerves are exclusively derived from gut ganglia. 
Our finding thus suggests that no marked overall changes in the intrinsic 
nervous system are induced by UC. This conclusion is substantiated by lack of 
changes in specimens stained for GAP-43, which reveals the entire nerve fiber 
population. Thus, UC does not seem to induce significant quantitative changes 
in muscular innervation. This contrasts with previous findings on thickened 
nerve fibers in the muscle layer of Crohn´s disease patients 119; 172 suggesting 
some differences in the pathogenesis of these two states of inflammatory 
bowel disease. 
 
To examine whether UC is associated with increased size of myenteric plexus 
ganglia, we measured the cumulative area of ganglion profiles per unit length 
in sections stained for NSE. The need for these measurements was suggested 
by previous studies reporting on 2-3-fold increase in the number of myenteric 
ganglion cells both in Crohn´s disease 172 and UC 20. In our study, no evidence 
for ganglion hypertrophy was obtained. The reported tendency for greater 
values of neuron numbers in UC specimens may be due to shrinkage known to 
occur in UC colon. 
 
 
SUBSTANCE P AND NEUROGENIC INFLAMMATION IN ULCERATIVE 
COLITIS 
 
Substance P-immunoreactive fibers in the enteric nervous system originate 
from both the intrinsic (gut ganglia) and extrinsic neurons (primary sensory 
neurons in the dorsal root ganglia). The intrinsic neurons are quantitatively the 
most important source of the substance P-containing nerves projecting to 
mucosal and submucosal blood vessels, mucosal epithelium, the muscle 
layers, and they also provide interganglionic connections. The extrinsic 
neurons connect to the gut via sympathetic (splanchnic and hypogastric) and 
sacral parasympathetic (pelvic) nerves and project to the submucosal and 
mucosal blood vessels 56. The present observations, although confirming the 
finding that the density of substance P-containing nerves is raised by 100-300 
% in UC, raise the question which component is responsible for the increased 
number of substance P fibers. 
 
In Hirschsprung disease the agangliotic segment lacks substance P-
immunoreactive nerves in the muscle layer and no neurons are found in the 
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submucous and myenteric plexi. In contrast, nerves in the lamina propria show 
normal density. Thus, the conclusion can been made that most of the 
substance P nerves in the mucosa are extrinsic 173. Our results do not favor the 
conclusion that the increase in substance P occurs in intrinsic fibers. Namely, 
no increase in the intensity of substance P immunoreactivity in the submucous 
or myenteric ganglia was observed, neither was the density of substance P 
nerves in the circular muscle, another target of the intrinsic neurons, affected 
by UC. The possibility remains that these fibers are extrinsic sensory fibers, 
since also other inflammatory processes, such as psoriasis, arthritis and 
asthma involve a similar increase in substance P immunoreactivity of sensory 
nerves 79-81. Unfortunately, we could not address this question directly, since 
the neurochemical identification of sensory nerves, i.e. colocalization of 
substance P and CGRP, does not hold for human gut 174; 175. We interpret that 
the increased density of substance P fibers is due to increased peptide 
synthesis, and consequently increased visibility of the fibers. Sprouting caused 
by UC cannot be excluded, although is unlikely, since it should show as an 
increased immunoreactivity of GAP-43 92. 
 
Sensory nerve fibers are known to secrete substance P from their peripheral 
process 76. Our observation provides a morphological substantiation for the 
hypothesis that substance P has an important role in ulcerative colitis. This 
hypothesis has gained extensive support from the following observations: A 
recent experimental study in mice has shown that neutral endopeptidase, a cell 
surface enzyme that degrades substance P in the extracellular fluid, termi nates 
dinitrobenzene sulfonic acid-induced colitis in wild type mice 84. In the neutral 
endopeptidase knockout mice substance P concentrations were higher and 
inflammation worse than in wild type mice. Recombinant neutral 
endopeptidase and substance P receptor antagonist prevented the 
exacerbated inflammation in knockout mice. Furthermore, the expression of 
NK1 binding sites by blood vessels and lymphoid aggregates is increased in 
inflammatory bowel disease 82; 118. Substance P has been found to enhance 
mast cell-mediated secretion in active UC, but not in normal mucosa 176. Mast 
cell hyperplasia in the gut is a well-known feature of inflammatory bowel 
disease 177. Furthermore, increased histamine release has been found in UC 
178
. Topical treatment with lidocaine gel in patients with ulcerative proctitis for 3-
8 weeks caused a rapid decrease of subjective and objective symptoms. 179. 
The present study strengthens the theoretical basis to suggest the use of 
substance P antagonists in treatment of UC. 
 
 
ULCERATIVE COLITIS INDUCES SELECTIVE REDUCTION OF NEURONAL 
NOS 
 
NOS-1 in the normal colon 
Our results on the distribution of NOS-1 in the normal human colon are in line 
with the previous reports on human colon 14; 15. We extended these findings by 
the observations that the submucous ganglion neurons lacked NOS-1 
immunoreactivity, while a proportion varying from 0 to 30 % of the cells in each 
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myenteric ganglion profile were NOS-1-reactive. Based on these findings it can 
be estimated that intrinsic NOergic innervation of the human colon is derived 
from a population of myenteric neurons comprising about 10-20 % of all 
myenteric neurons.  
 
NOS-1-immunoreactive nerve fibers formed a dense innervation pattern in the 
inner, circular muscle layer and the muscularis mucosae and somewhat less 
densely innervated the outer, longitudinal muscle layer. The lamina propria was 
devoid of NOS-1-immunoreactive fibers and the submucosa only rarely 
showed nerve terminals. The fiber bundles seen in the submucosa are 
probably formed by the axons traversing the submucosa on their way to 
muscularis mucosae. Notably, no perivascular NOS-immunoreactive 
innervation was observed. By contrast, staining with GAP-43 antibody showed 
abundant nerve terminals in the lamina propria and in the submucosa, 
including those around the blood vessels. Thus, our findings suggest that the 
NOS-containing neurons in human colon primarily contribute to the innervation 
of intestinal smooth muscle, but do not seem to have any direct role in the 
regulation of secretion or blood flow. In experimental animals, NO produced by 
NOS-1 mediates muscle relaxation through inhibitory junction potential 16; 17; 43. 
In the human colon, the role of NOS-1 is less clear: inhibition of NOS reduces 
non-adrenergic, non-cholinergic relaxation, although the inhibitory junction 
potential is not affected 18; 85; 180. 
 
NOS-1 in ulcerative colitis 
Disappearance or marked reduction in the number of NOS-1-immunoreactive 
nerve fibers in the muscularis mucosae was found in UC specimens. In 
contrast, no corresponding change was seen in GAP-43- or VIP-stained 
sections. Moreover, no change in GAP-43 staining pattern was observed in the 
circular or longitudinal muscle layers. These results demonstrate that UC 
affects the NOergic innervation specifically in the muscularis mucosae. Our 
results are supported by a recent report on reduced number of NOS-containing 
neurons in colonic wall in experimental rat colitis 181. Two separate 
mechanisms can be envisaged behind this change: NOS-1-containing nerve 
fibers may truly disappear or their NOS-1 expression is specifically down 
regulated in UC. The latter alternative is favored by the observation that no 
change was observed in the innervation of muscularis mucosae, either as 
visualized by VIP, a neuropeptide largely colocalizing with NOS 15 or GAP-43, a 
general neuronal marker. Reduction of muscularis mucosae NOS-1 content in 
UC may be accompanied with reduced sensitivity to arachidonic acid 
metabolites and/or reduced excitation-contraction coupling 182, although the 
causal relationship of these phenomena remains to be elucidated.  
 
 
INDUCTION OF NOS-2 IN ULCERATIVE COLITIS 
 
NOS-2 is the inducible NOS isoform, which has been localized, in activated 
macrophages, neutrophils and several other cell types 36. Previous studies 
report that normal human colon lacks NOS-2 26; 132-134. Our study by and large 
 Discussion 
 
 
51
confirms this conclusion, although we regularly observed slight NOS-2 
immunoreactivity in the epithelium of some crypts in about half the specimens 
of normal colon. The difference between the control and UC specimens was 
marked, and the appearance of NOS-2 immunoreactivity in the epithelium 
clearly correlated with the degree of the disease. Previously, contradictory 
results have been published, some studies showing association of NOS-2 
immunoreactivity with the degree of UC 132; 134, others reporting lack of such 
association 26. Lack of NOS-2 immunoreactivity in normal colon or in mild UC in 
the previous studies is likely due to differences in the sensitivity of the 
immunohistochemical methodology. There is some discrepancy as for NOS-2 
expression in the cells of lamina propria or submucosa in UC specimens. We, 
like Dijkstra and coworkers, 134 did not observe but few NOS-2-immunoreactive 
cells, while others report such reactivity in a minority of inflammatory cells 26 or 
even in several different cells types 132; 133; 183; 184. Varying medication of the 
patients or differences in the specificity of the technique may be responsible for 
these differences. Several studies have failed to show rapid expression of nitric 
oxide synthase or production of NO in human macrophages 185. 
 
Expression of NOS-2 in the colon epithelium, particularly in the apical region, in 
UC is compatible with some protective function of NOS in the injured 
epithelium. This idea is supported, on one hand, by development of 
exacerbated UC in NOS-2 deficient mice 137 or in mice treated with NOS-2 
inhibitor 138 and, on the other hand, enhanced anti-inflammatory effect of NO-
releasing derivative of 5-ASA 139. Induction of NOS-2 in the apical epithelium 
may also be a cause for inhibited bacterial invasion in UC 186. However excess 
of NO can react with superoxide and produce peroxynitrite. Studies using 
inhibitors of NOS in experimental colitis would suggest that inhibition of NO 
production will reduce the intestinal inflammation and destruction 140; 141 NOS-2 
may be responsible for increased permeability observed in UC 187, since in 
experimental animals NO donor induced hyperpermeability of cultured 
epithelial monolayers 188 and inhibition of NOS-2 prevents endotoxin-induced 
increase in gut permeability 189. 
 
 
REGIONAL DIFFERENCES IN ENDOTHELIAL NOS DISAPPEAR IN 
ULCERATIVE COLITIS 
 
As expected, NOS-3 was localized exclusively in the vascular endothelium. 
Surprisingly, the staining intensity of lamina propria vessels in the normal colon 
was consistently higher than that of submucosal vessels. This difference may 
represent local regulation by either blood-borne agonists activating endothelial 
receptors, by shear stress caused by increased blood flow, or by low oxygen 
tension 47; 48. In line with progressive neovascularization occurring in UC, mild 
disease caused no changes in the distribution of NOS-3, while an increased 
number of vascular profiles were evident in moderate UC. Decrease in the 
intensity of vascular NOS-3 immunoreactivity in the lamina propria of UC 
specimens suggests a disturbance in the local regulation of blood flow.  
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NOS-2 CONTENT IN POUCHITIS CORRELATES TO THE CLINICAL 
DEGREE OF DISEASE 
 
No-pouchitis group 
We compared the distribution of NOS-2 immunoreactivity in the terminal ileum 
of UC patients and in the ileal reservoir of the no-pouchitis group 4 to 86 
months after the operation. By microscopic examination, occasional villi 
showed NOS-2-immunoreactive regions in both groups but the difference in 
NOS-2 immunoreactivity score was nonsignificant. In accordance, we obtained 
no significant differences in the acute inflammation scores between the control 
ileum and the no-pouchitis group. These observations indicate that 
construction of the reservoir per se does not induce significant NOS-2 
expression. 
 
Pouchitis groups 
Acute inflammation score based on neutrophil infiltration was increased in all 
pouchitis groups. Villus atrophy in all pouchitis groups was observed here, as 
well as in previous studies 127; 190. These findings confirm that acute 
inflammation was in progress in all three pouchitis groups studied here, 
although the clinical course and the symptoms were different in each group.  
 
Like in UC, we demonstrated that NOS-2 immunoreactivity is also induced in 
the epithelium of the inflamed ileal reservoir. NOS-2 immunoreactivity score 
correlated significantly with acute inflammation score based on neutrophil 
infiltration. NOS-2 immunoreactivity also correlated in the present study with 
clinically estimated severity of pouchitis. Although induction of NOS-2 is not 
specific for UC 26; 45; 46; 191, changes in NOS and substance P in UC and 
pouchitis suggest similarities in pathogenesis of the two diseases. Taken 
together, our results suggest that NOS-2 immunoreactivity provides a useful 
marker for pouchitis. NOS-2 would be a more accurate indicator of pouchitis 
than substance P, since the latter remains elevated irrespective of clinical 
improvement of pouchitis 126. 
 
 
NOS-2 INDUCTION IN POUCHITIS AS A DEFENCE MECHANISM 
 
Inducible NOS in pouchitis may have protective functions in the injured ileal 
epithelium. This hypothesis is supported by analogy from observation on UC. 
Although direct conclusions regarding human UC cannot be drawn, a similar 
protective role is feasible, since NOS-2 immunoreactivity was conspicuously 
localized in the apical epithelium both in human colitis and in pouchitis. 
 
The evidence for a role of bacterial invasion in the pathogenesis of UC or 
pouchitis is contradictory. Continent pouch contains more extensive bacterial 
growth than normal ileum content, and pouchitis responds readily to 
antimicrobial therapy 192; 193. Intramural bacteria have been described electron 
microscopically in 47 % of patients with a pouch, irrespective of whether the 
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patients developed pouchitis 194. In contrast, no bacterial invasion was reported 
in UC patients, while increased bacterial growth was observed on the surface 
mucus 186 and mucosal IgG antibodies against commensal enteral bacteria are 
increased in UC 195. Enteroinvasive bacteria are known to induce directly NOS-
2 expression in human colon epithelial cells and to result in NO production 
primarily in the apical part of the epithelial cell 196. Increased NO generation 
caused by cytokines, bacterial products or mitogens has also been reported in 
cultured small intestinal epithelial cells 197. Taken together, increased 
expression of NOS-2 in relation to the severity of pouchitis may represent 
activation of epithelial NOergic defense mechanism against bacterial invasion 
in pouchitis.  
 
Permeability of the mucosa is increased in pouchitis 198. Increased intestinal 
permeability after thermal injury is correlated with induced NOS-2 activity, 
which is localized mainly in enterocytes and which is prevented by S-
methylthiourea, a specific NOS-2 inhibitor 135. Nitric oxide donor induces 
hyperpermeability of cultured intestinal epithelial monolayers 188. These 
observations suggest that NO production by the induced NOS-2 observed in 
the present study may be the cause of increased permeability in pouchitis. 
 
 
NOS-3 IN POUCHITIS  
 
Endothelial NOS immunoreactivity readily revealed the vasculature in the 
lamina propria, thus the increase in the number of vascular profiles was 
expected in pouchitis specimens. While the villus core in the normal ileum and 
no-pouchitis groups only rarely showed NOS-3-immunoreactive vascular 
profiles, such profiles were common in the pouchitis groups (3-5). This is 
surprising, since the endothelium is thought to express NOS-3 uniformly. 
Appearance of NOS-3-immunoreactive vessels in the villus core in pouchitis 
might represent increased NOS-3-acitivity and/or vascular proliferation due to 
inflammation. A less likely explanation is that NOS is induced by pouchitis in 
villus endothelium not normally expressing it. Increased NOS-3 
immunoreactivity in pouchitis may reflect changes in pouch microcirculation. 
 
 
NERVE TERMINALS CONTAINING NEUROPEPTIDES DECREASE IN 
NUMBER AFTER MASSIVE SMALL BOWEL RESECTION 
 
After massive small bowel resection, the remaining intestine undergoes both 
morphological and functional changes to obtain sufficient absorption of 
nutrients. 29-31; 144. The mechanisms for the marked motor and secretory 
changes that follow small bowel resection are largely unknown. 
 
Massive small bowel resection caused a significant decrease in the number of 
VIP-immunoreactive nerves in the mucosa and the circular muscle. This is in 
accordance with the findings on reduced VIP tissue concentration in dogs 
subjected to massive resection of the small bowel 159. In the rat, massive small 
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bowel resection caused an increase in the number of VIP-immunoreactive 
neurons in the submucosal ganglia, and this change was accompanied by 
increased ganglion and neuron size 158. Nerve fibers were not investigated in 
that study. In the light of the present study, this observation probably 
represents increased VIP synthesis in such interneurons, which do not project 
outside the ganglia and which normally express no or only very low levels of 
VIP.  
 
VIP is a potent stimulant of intestinal secretion 86. It acts directly via VIP 
receptors activating production of cAMP in enterocytes to increase intestinal 
secretion. However, rat small intestine shows decreased affinity of VIP 
receptors after resection 199. This observation, together with the present result, 
predicts that VIP-induced secretion is impaired after resection. Moreover, it is 
consistent with the known inhibitory role of cAMP on cell proliferation in the 
epithelium and suggests participation of VIP in the compensatory 
hyperproliferative response of the remaining intestine following massive 
resection of the small intestine.  
 
Normally VIP-containing nerve terminals contribute to the peristaltic reflex so 
that their projections mediate descending inhibition of the reflex, while 
substance P contributes to the stimulatory effect. Extensive proximal resection 
causes a decrease in the motility of the remnant intestine, resulting in 
compensatory improvement of absorptive function 156; 157. Our finding that the 
density of VIP-immunoreactive (inhibitory) nerve fibers decreases while that of 
substance P-immunoreactive (stimulatory) fibers remains unchanged would 
predict the opposite. 
 
In the pig, progressive decrease in plasma levels of VIP has been measured 
after massive small bowel resection 200. In accordance, the portal release of 
VIP is inhibited in resected gut in the dog 201. The decrease in the number of 
VIP-immunoreactive fibers observed in this study may be related to decreased 
plasma concentration of VIP by diminished secretory activity of VIP neurons. In 
contrast, human plasma levels of VIP are elevated in short bowel syndrome. 
Several factors have been suggested to contribute to this: an increased gastric 
load in the residual bowel, a compensatory increase in blood supply to the gut, 
removal of an inhibitory factor arising in the small intestine, or mucosal stress 
of the colon due to unabsorbed food 202.  
 
The resection failed to induce any quantitative changes in galanin 
immunoreactivity in the mucosa. Galanin inhibits, in part, the release of 
hormones in the gastrointestinal tract. Postprandial enteroglucagon and PYY 
plasma concentration decrease during galanin infusion and increase after 
resection 203; 204. Lack of resection-induced changes in galanin 
immunoreactivity in the mucosa suggests that enteroglucagon and PYY levels 
are only partially regulated by galanin. However, the number of galanin-
immunoreactive nerves in the muscle layer decreased markedly after the 
resection. Galanin inhibits intestinal smooth muscle contractility in the human 
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and in several animal species 203; 205. Thus, the effect of galanin in resected gut 
is synergistic with that of VIP.  
 
Enkephalin-immunoreactive nerves were observed only in the muscle layer. In 
the 5-month-old control pigs, we observed significantly more enkephalin-
containing nerves than in 3-month-old piglets. On the other hand, the 
distribution of enkephalin in the 5-month-old operated piglets was similar to the 
3-month-old-old control piglets. Thus the increase in the density of enkephalin 
innervation during natural development is inhibited by the resection. 
Enkephalin is one of the opioid peptides that have numerous and complex 
effects on gut motility, such as delaying whole gut transit time and gastric 
emptying and inhibition of gastric contraction. Thus, the well-known clinical 
effect of opioids in treatment of diarrhea suggests that one physiological 
function of the endogenous opioid peptides is to limit the intensity of intestinal 
excitation and thus decelerate gut motility 70. The present observation on the 
decreased number of enkephalin-immunoreactive nerve fibers in the remnant 
gut as compared to the age-matched control indicates that enkephalin-
mediated effects are decreased due to the resection. This parallels with 
alteration in VIP-and galanin-mediated effects. Hence, all three neuropeptides 
have inhibitory effects on the intestinal motility and resection diminishes these 
effects. The mechanisms of the overall decrease in the motility after proximal 
resection, as reported in previous studies, remains unknown 156; 157. However, 
the reduction of inhibitory neuropeptides may reflect changes in propulsive and 
mixing peristalsis in short bowel syndrome. 
 
The distribution of substance P and somatostatin-immunoreactive nerves was 
similar in all three groups. Although minute changes may be missed by visual 
estimation, our observation suggests that these two neuropeptides do not 
essentially contribute to the changes induced by resection. Previous studies 
give only fragmentary information on their effects. An increase in the size of 
submucosal somatostatin-immunoreactive neurons after massive small bowel 
resection in the rat has been reported 158. In contrast, in the dog no change in 
somatostatin tissue concentration in the remaining small intestine was found 
after massive distal resection 159. 
 
The results of our study suggest that massive resection induces significant 
changes in the neuropeptide-containing innervation in the mucosa and muscle 
layer. The changes are specific for VIP, galanin, and enkephalin and most 
probably contribute to altered motor activity and altered mucosal function in the 
remaining intestine. 
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CONCLUSIONS 
 
1. GAP-43 is a universal neuronal marker in the mature human enteric 
nervous system. GAP-43 immunoreactivity reveals more numerous and 
thicker nerve fibers than PGP 9.5, synaptophysin, or NSE 
immunoreactivities although the true staining intensity is essentially similar 
for all these markers. In contrast, NSE is a superior marker of neuronal 
somata.  
 
2. The present study corroborated the special role of substance P in UC. 
Ulcerative colitis does not significantly change the total number of nerve 
fibers in the colon. In contrast, the density of substance P-containing nerve 
terminals increases specifically This occurs exclusively in the mucosa, and 
is likely due to increased peptide synthesis leading to better visibility of the 
nerve fibers.  
 
3. The present study demonstrates that NO affects the function of colon by 
several mechanisms: Neuronal NOS (NOS-1) disappears selectively from 
the nerves of muscularis mucosae of UC colon. Inducible NOS (NOS-2) 
content increases in the epithelium of UC colon in relation to the severity of 
the disease. Ulcerative colitis causes an increase in the number of vascular 
profiles, and a relative decrease in the level of endothelial NOS (NOS-3) in 
the lamina propria. 
 
4. Expression of inducible NOS correlates with both the clinical degree of 
pouchitis and with the severity of acute inflammation.  
 
5. Massive resection induces significant changes in the neuropeptide-
containing innervation in the mucosa and muscle layer. The changes are 
specific for VIP, galanin, and enkephalin and are compatible with altered 
motor activity and altered mucosal function in the remaining intestine. 
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